{"entity":{"id":"2017","kind":"year","name":"2017 in oncology","aka":["2017"],"tldr":"Everything OnCo dates to 2017: 629 entries, 166 papers, 152 papers listed on people's pages, 130 landmarks and 75 trials reported. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"629 dated entries in OnCo fall in 2017: 166 papers, 152 papers listed on people's pages, 130 landmarks, 75 trials reported, 53 approvals, 23 regulatory events, 16 companies founded, 5 technologies, 4 journals founded, 3 laws and regulations and 2 guideline changes.\n\nOf those, 20 to the day, 5 to the month and 604 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2016","2018"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2017,"events":[{"group":"approval","date":"2017","precision":"year","title":"5-Aminolevulinic acid (oral, for glioma surgery) approved in US","note":"Imaging agent for visualisation of malignant tissue during glioma surgery (suspected high-grade)","from":"aminolevulinic-acid-gleolan","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Abemaciclib approved in US","note":"HR+/HER2- advanced breast cancer","from":"abemaciclib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Acalabrutinib approved in US","note":"Relapsed MCL (accelerated)","from":"acalabrutinib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Alectinib approved in US","note":"First-line ALK+ NSCLC","from":"alectinib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Avelumab approved in US","note":"Merkel cell carcinoma; urothelial cancer after platinum (accelerated)","from":"avelumab","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Axicabtagene ciloleucel approved in US","note":"Relapsed/refractory large B-cell lymphoma ≥2 lines","from":"axicabtagene-ciloleucel","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Bosutinib approved in US","note":"Newly diagnosed Ph+ CML chronic phase","from":"bosutinib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Brigatinib approved in US","note":"ALK-positive metastatic NSCLC after crizotinib","from":"brigatinib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Cabozantinib approved in US","note":"First-line advanced RCC (CABOSUN)","from":"cabozantinib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Ceritinib approved in US","note":"First-line ALK-positive metastatic NSCLC","from":"ceritinib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Cetuximab approved in England (NICE)","note":"Previously untreated EGFR-expressing RAS wild-type metastatic colorectal cancer with FOLFOX or FOLFIRI.","from":"cetuximab","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Copanlisib approved in US","note":"Relapsed follicular lymphoma after ≥2 therapies. Withdrawn 2023","from":"copanlisib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"CPX-351 (liposomal daunorubicin-cytarabine) approved in US","note":"Newly diagnosed therapy-related AML or AML with myelodysplasia-related changes, adults","from":"cpx-351","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Dabrafenib + trametinib approved in US","note":"BRAF V600E metastatic NSCLC","from":"dabrafenib-trametinib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Dinutuximab (ch14.18) / dinutuximab beta approved in EU","note":"Dinutuximab beta: high-risk neuroblastoma after induction/transplant; relapsed/refractory disease","from":"dinutuximab","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Durvalumab approved in US","note":"Locally advanced or metastatic urothelial carcinoma after platinum (accelerated; indication withdrawn 2021)","from":"durvalumab","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Enasidenib approved in US","note":"Relapsed/refractory IDH2-mutated AML","from":"enasidenib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Fluciclovine F-18 approved in EU","note":"Same","from":"fluciclovine-f18","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"FoundationOne CDx / Liquid CDx approved in US","note":"Tissue CGP companion diagnostic (Liquid CDx 2020)","from":"foundationone-cdx","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Fulvestrant approved in US","note":"First-line HR+ advanced breast cancer (FALCON)","from":"fulvestrant","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Gallium-68 DOTATATE (and Cu-64 DOTATATE) approved in EU","note":"SomaKit TOC (Ga-68 DOTATOC)","from":"ga68-dotatate","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Gemtuzumab ozogamicin approved in US","note":"Newly diagnosed and relapsed CD33+ AML","from":"gemtuzumab-ozogamicin","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Inotuzumab ozogamicin approved in US","note":"Relapsed/refractory CD22+ B-ALL, adults","from":"inotuzumab-ozogamicin","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Lenalidomide approved in US","note":"Maintenance after autologous transplant","from":"lenalidomide","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Liposomal irinotecan approved in UK","note":"Metastatic adenocarcinoma of the pancreas after gemcitabine-based therapy, with fluorouracil and leucovorin: NICE TA440 (26 April 2017) does not recommend it within its marketing a...","from":"liposomal-irinotecan","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Lutetium-177 dotatate approved in EU","note":"First approval globally (Sep 2017)","from":"lutathera","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Mechlorethamine (chlormethine) approved in EU","note":"Topical treatment of mycosis fungoides-type CTCL (Ledaga)","from":"mechlorethamine","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Midostaurin approved in US","note":"Newly diagnosed FLT3-mutated AML with 7+3 and consolidation; advanced systemic mastocytosis","from":"midostaurin","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Nab-paclitaxel approved in UK","note":"Untreated metastatic adenocarcinoma of the pancreas with gemcitabine; NICE TA476 (6 September 2017, replacing TA360) recommends it only if other combination chemotherapies are unsu...","from":"nab-paclitaxel","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Neratinib approved in US","note":"Extended adjuvant HER2+ early breast cancer after trastuzumab","from":"neratinib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Niraparib approved in US","note":"Recurrent ovarian cancer maintenance","from":"niraparib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Oncomine Dx Target Test approved in US","note":"Companion diagnostic for BRAF, ROS1 and EGFR-directed therapies in NSCLC","from":"oncomine-dx-target-test","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Padeliporfin approved in EU","note":"Unilateral, low-risk, previously untreated prostate adenocarcinoma in men with life expectancy of at least 10 years (Tookad VTP)","from":"padeliporfin","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Panitumumab approved in England (NICE)","note":"Previously untreated RAS wild-type metastatic colorectal cancer with FOLFOX or FOLFIRI. TA439 recommends panitumumab within its marketing authorisation subject to the patient acces...","from":"panitumumab","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"PD-L1 IHC 22C3 pharmDx approved in US","note":"Gastric / GEJ adenocarcinoma, CPS ≥1","from":"dako-pd-l1-22c3-pharmdx","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Pembrolizumab approved in England (NICE)","note":"Locally advanced or metastatic PD-L1-positive non-small-cell lung cancer after at least one chemotherapy.","from":"pembrolizumab","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Pembrolizumab approved in US","note":"MSI-H/dMMR solid tumours (tumour-agnostic)","from":"pembrolizumab","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Pertuzumab approved in US","note":"Adjuvant HER2+ early breast cancer at high risk of recurrence","from":"pertuzumab","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Regorafenib approved in US","note":"HCC previously treated with sorafenib","from":"regorafenib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Ribociclib approved in US","note":"HR+/HER2- advanced breast cancer","from":"ribociclib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Sunitinib approved in US","note":"Adjuvant RCC at high risk (S-TRAC), little used","from":"sunitinib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Telotristat ethyl approved in EU","note":"Same (Xermelo)","from":"telotristat-ethyl","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Telotristat ethyl approved in US","note":"Carcinoid syndrome diarrhoea with somatostatin analogue therapy in adults inadequately controlled by SSA alone","from":"telotristat-ethyl","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Thiotepa approved in US","note":"Conditioning before allogeneic HSCT for class 3 beta-thalassaemia in children (Tepadina)","from":"thiotepa","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Tisagenlecleucel approved in US","note":"Relapsed/refractory B-ALL, patients up to 25 years","from":"tisagenlecleucel","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Tivozanib approved in EU","note":"EU first (Aug 2017)","from":"tivozanib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Tocilizumab approved in US","note":"Severe or life-threatening CAR-T-cell-induced cytokine release syndrome, age 2 and over","from":"tocilizumab","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Transpara approved in EU","note":"CE mark, mammography decision support","from":"transpara","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Trastuzumab biosimilars approved in EU","note":"Ontruzant, first EU trastuzumab biosimilar","from":"trastuzumab-biosimilars","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Trastuzumab biosimilars approved in US","note":"First trastuzumab biosimilar (Ogivri); all trastuzumab indications","from":"trastuzumab-biosimilars","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"Vemurafenib approved in US","note":"Erdheim-Chester disease with BRAF V600 mutation","from":"vemurafenib","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"VENTANA PD-L1 (SP263) Assay approved in EU","note":"CE-IVD with claims for several PD-1/PD-L1 antibodies","from":"ventana-pd-l1-sp263","refs":[]},{"group":"approval","date":"2017","precision":"year","title":"VENTANA PD-L1 (SP263) Assay approved in US","note":"Complementary PD-L1 assay for durvalumab in urothelial carcinoma","from":"ventana-pd-l1-sp263","refs":[]},{"group":"company","date":"2017","precision":"year","title":"Everest Medicines founded","note":"Shanghai","from":"everest-medicines","refs":[]},{"group":"company","date":"2017","precision":"year","title":"GenFleet Therapeutics founded","note":"Shanghai","from":"genfleet","refs":[]},{"group":"company","date":"2017","precision":"year","title":"German Lymphoma Alliance founded","note":"Homburg","from":"german-lymphoma-alliance","refs":[]},{"group":"company","date":"2017","precision":"year","title":"Gracell Biotechnologies founded","note":"Suzhou","from":"gracell-biotechnologies","refs":[]},{"group":"company","date":"2017","precision":"year","title":"HotSpot Therapeutics founded","note":"Boston, Massachusetts","from":"hotspot-therapeutics","refs":[]},{"group":"company","date":"2017","precision":"year","title":"IASO Biotherapeutics founded","note":"Nanjing / Shanghai","from":"iaso-bio","refs":[]},{"group":"company","date":"2017","precision":"year","title":"iOnctura founded","note":"Geneva","from":"ionctura","refs":[]},{"group":"company","date":"2017","precision":"year","title":"Mabwell (Shanghai) Bioscience founded","note":"Shanghai","from":"mabwell-shanghai-bioscience","refs":[]},{"group":"company","date":"2017","precision":"year","title":"Mythic Therapeutics founded","note":"Waltham, MA","from":"mythic-therapeutics","refs":[]},{"group":"company","date":"2017","precision":"year","title":"Naveris founded","note":"Waltham, MA","from":"naveris","refs":[]},{"group":"company","date":"2017","precision":"year","title":"Outcomes4Me founded","note":"Boston, MA","from":"outcomes4me","refs":[]},{"group":"company","date":"2017","precision":"year","title":"QBiotics founded","note":"Toowong, Brisbane","from":"qbiotics","refs":[]},{"group":"company","date":"2017","precision":"year","title":"Quantum Surgical founded","note":"Montpellier","from":"quantum-surgical","refs":[]},{"group":"company","date":"2017","precision":"year","title":"Section 32 (S32) founded","note":"San Diego, CA","from":"section-32","refs":[]},{"group":"company","date":"2017","precision":"year","title":"Toshiba Energy Systems & Solutions founded","note":"Kawasaki","from":"toshiba-energy-systems","refs":[]},{"group":"company","date":"2017","precision":"year","title":"TYK Medicines founded","note":"Shanghai","from":"tyk-medicines","refs":[]},{"group":"history","date":"2017","precision":"year","title":"A single flexible sigmoidoscopy still protects 17 years later","note":"Colorectal cancer. The UK Flexible Sigmoidoscopy Screening Trial, 170,034 people, reported a 26 percent lower incidence and a 30 percent lower mortality in those invited, and 35 an...","from":"colorectal","refs":["colorectal-screening","colonoscopy"]},{"group":"history","date":"2017","precision":"year","title":"Acalabrutinib approved (ACE-LY-004)","note":"Mantle cell lymphoma","from":"mantle-cell-lymphoma","refs":["acalabrutinib"]},{"group":"history","date":"2017","precision":"year","title":"AGCT1531 opens","note":"Germ cell tumours of childhood and adolescence (extracranial and CNS). Joint COG/CCLG trial of active surveillance and carboplatin versus cisplatin.","from":"paediatric-germ-cell-tumours","refs":["carboplatin","cisplatin"]},{"group":"history","date":"2017","precision":"year","title":"AJCC 8th edition adds the prognostic stage","note":"Triple-negative breast cancer (TNBC). Grade, ER, PR and HER2 enter the stage group alongside TNM (Giuliano, CA); validated in 2018.","from":"tnbc","refs":["ajcc-prognostic-stage-breast"]},{"group":"history","date":"2017","precision":"year","title":"AJCC and UICC 8th edition","note":"Gallbladder cancer. T2 is split into T2a and T2b and N stage is defined by the number of involved nodes (N1 one to three, N2 four or more).","from":"gallbladder","refs":["tnm-staging","t2a-versus-t2b","paper-chun-ajcc-8th-edition-hepatobiliary-aso-2018"]},{"group":"history","date":"2017","precision":"year","title":"ALCANZA: brentuximab in CD30+ CTCL","note":"Peripheral T-cell lymphomas (including cutaneous T-cell lymphoma)","from":"peripheral-t-cell-lymphoma","refs":["brentuximab-vedotin"]},{"group":"history","date":"2017","precision":"year","title":"ALCANZA: brentuximab vedotin beats standard therapy in CD30-positive disease","note":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","from":"cutaneous-t-cell-lymphoma","refs":["brentuximab-vedotin"]},{"group":"history","date":"2017","precision":"year","title":"ALEX: alectinib beats crizotinib first line with far less brain progression","note":"ALK-positive non-small-cell lung cancer","from":"alk-positive-nsclc","refs":["alex","alectinib","solange-peters"]},{"group":"history","date":"2017","precision":"year","title":"APHINITY: adjuvant pertuzumab helps node-positive disease","note":"Early HER2-positive breast cancer","from":"her2-positive-early-breast-cancer","refs":["aphinity","pertuzumab"]},{"group":"history","date":"2017","precision":"year","title":"Aqueous humour as liquid biopsy (Berry)","note":"Retinoblastoma","from":"retinoblastoma","refs":["liquid-biopsy"]},{"group":"history","date":"2017","precision":"year","title":"Autologous transplant equals WBRT with less neurotoxicity","note":"Primary CNS lymphoma. IELSG32 second randomisation and PRECIS.","from":"primary-cns-lymphoma","refs":["autologous-stem-cell-transplant"]},{"group":"history","date":"2017","precision":"year","title":"Avelumab: first approved therapy for MCC","note":"Merkel cell carcinoma. JAVELIN Merkel 200; accelerated approval March 2017.","from":"merkel-cell-carcinoma","refs":["avelumab"]},{"group":"history","date":"2017","precision":"year","title":"Axi-cel CAR-T approved","note":"Diffuse large B-cell lymphoma","from":"dlbcl","refs":["axicabtagene-ciloleucel"]},{"group":"history","date":"2017","precision":"year","title":"Axi-cel: first CAR-T approved for large B-cell lymphoma (ZUMA-1)","note":"Diffuse large B-cell lymphoma","from":"dlbcl","refs":["axicabtagene-ciloleucel","car-t"]},{"group":"history","date":"2017","precision":"year","title":"Axicabtagene ciloleucel approved for large B-cell lymphoma, including primary mediastinal disease","note":"Primary mediastinal (thymic) large B-cell lymphoma","from":"primary-mediastinal-b-cell-lymphoma","refs":["axicabtagene-ciloleucel","car-t"]},{"group":"history","date":"2017","precision":"year","title":"BILCAP: adjuvant capecitabine adopted","note":"Biliary tract cancer (cholangiocarcinoma)","from":"cholangiocarcinoma","refs":["bilcap"]},{"group":"history","date":"2017","precision":"year","title":"CATNON: adjuvant temozolomide after radiotherapy for grade 3 non-codeleted glioma","note":"Astrocytoma, IDH-mutant (grades 2 to 4)","from":"idh-mutant-astrocytoma","refs":["catnon","temozolomide"]},{"group":"history","date":"2017","precision":"year","title":"CHIC international risk stratification (Lancet Oncol)","note":"Hepatoblastoma","from":"hepatoblastoma","refs":[]},{"group":"history","date":"2017","precision":"year","title":"Children's Oncology Group shows excision alone is enough for completely resected stage IA disease in children","note":"Nodular lymphocyte-predominant Hodgkin lymphoma (nodular lymphocyte-predominant B-cell lymphoma)","from":"nodular-lymphocyte-predominant-hodgkin-lymphoma","refs":["childrens-oncology-group"]},{"group":"history","date":"2017","precision":"year","title":"COMBI-AD and CheckMate 238 establish adjuvant therapy for stage III; MSLT-II ends completion dissection","note":"Melanoma","from":"melanoma","refs":["combi-ad","mslt-ii"]},{"group":"history","date":"2017","precision":"year","title":"COMBI-AD: adjuvant dabrafenib-trametinib halves relapse risk; COMBI-MB shows intracranial responses","note":"BRAF V600-mutant melanoma","from":"braf-v600-melanoma","refs":["combi-ad","dabrafenib-trametinib"]},{"group":"history","date":"2017","precision":"year","title":"CONVERT: 66 Gy once daily not superior to 45 Gy twice daily","note":"Limited-stage small-cell lung cancer","from":"limited-stage-sclc","refs":["convert","fiona-blackhall"]},{"group":"history","date":"2017","precision":"year","title":"CONVERT: once-daily 66 Gy not superior to twice-daily 45 Gy","note":"Small-cell lung cancer","from":"sclc","refs":["convert"]},{"group":"history","date":"2017","precision":"year","title":"CPX-351 approved after Study 301 lengthens life in secondary AML","note":"Secondary and therapy-related acute myeloid leukaemia","from":"aml-secondary","refs":["cpx-351-301","cpx-351"]},{"group":"history","date":"2017","precision":"year","title":"CREATE-X: capecitabine after residual disease lengthens survival","note":"Triple-negative breast cancer (TNBC). 910 patients; five-year overall survival 89.2 vs 83.6 percent, and 78.8 vs 70.3 percent in the triple-negative group.","from":"tnbc","refs":["paper-create-x-adjuvant-capecitabine-nejm-2017","capecitabine"]},{"group":"history","date":"2017","precision":"year","title":"CREATE-X: capecitabine for residual disease after neoadjuvant chemotherapy","note":"Early triple-negative breast cancer","from":"tnbc-early","refs":["capecitabine"]},{"group":"history","date":"2017","precision":"year","title":"Dabrafenib plus trametinib approved for BRAF V600E lung cancer after BRF113928","note":"BRAF V600E-mutant non-small-cell lung cancer","from":"braf-v600e-nsclc","refs":["dabrafenib-trametinib","david-planchard","novartis"]},{"group":"history","date":"2017","precision":"year","title":"Depth of invasion enters staging (AJCC 8th edition)","note":"Oral cavity cancer (mouth and tongue)","from":"oral-cavity-cancer","refs":[]},{"group":"history","date":"2017","precision":"year","title":"Depth of invasion enters staging (AJCC 8th edition)","note":"Oral tongue and floor of mouth cancer","from":"oral-tongue-cancer","refs":[]},{"group":"history","date":"2017","precision":"year","title":"DNA methylation classes of meningioma predict recurrence","note":"Meningioma. Sahm and colleagues (Lancet Oncology).","from":"meningioma","refs":["methylation-profiling"]},{"group":"history","date":"2017","precision":"year","title":"EBV DNA screening detects early NPC in 20,000 men (Chan, NEJM)","note":"Nasopharyngeal carcinoma","from":"nasopharyngeal","refs":[]},{"group":"history","date":"2017","precision":"year","title":"Eighth edition staging shows stage IIB and IIC outcomes worse than IIIA","note":"Stage IIB and IIC melanoma","from":"stage-ii-melanoma","refs":["breslow-thickness","ulceration-melanoma"]},{"group":"history","date":"2017","precision":"year","title":"Enasidenib: first IDH inhibitor approved, for relapsed IDH2-mutated AML","note":"IDH1- and IDH2-mutated acute myeloid leukaemia","from":"aml-idh","refs":["enasidenib"]},{"group":"history","date":"2017","precision":"year","title":"ESPAC-4: gemcitabine plus capecitabine beats gemcitabine alone after surgery","note":"Resectable pancreatic ductal adenocarcinoma","from":"resectable-pdac","refs":["gemcitabine","capecitabine"]},{"group":"history","date":"2017","precision":"year","title":"FDA approves pembrolizumab for any mismatch-repair deficient solid tumour, the first tissue-agnostic approval","note":"Mismatch-repair deficient (MSI-high) colorectal cancer","from":"msi-high-colorectal","refs":["pembrolizumab","tumour-agnostic"]},{"group":"history","date":"2017","precision":"year","title":"FIRES: sentinel node mapping validated; pembrolizumab approved for MSI-H tumours","note":"Endometrial cancer","from":"endometrial","refs":["fires-sentor","pembrolizumab","msi"]},{"group":"history","date":"2017","precision":"year","title":"First CAR-T for lymphoma","note":"Non-Hodgkin lymphoma (all types). Axicabtagene ciloleucel approved for relapsed large B-cell lymphoma after two or more lines.","from":"non-hodgkin-lymphoma","refs":["axicabtagene-ciloleucel"]},{"group":"history","date":"2017","precision":"year","title":"First CAR-T therapy approved","note":"Childhood cancers (all types). Tisagenlecleucel for children and young adults with relapsed or refractory B-cell acute lymphoblastic leukaemia.","from":"childhood-cancers","refs":["tisagenlecleucel"]},{"group":"history","date":"2017","precision":"year","title":"First genome-wide risk variants","note":"Gallbladder cancer. The Indian genome-wide association study finds common variants at ABCB1 and ABCB4 that raise gallbladder cancer risk.","from":"gallbladder","refs":[]},{"group":"history","date":"2017","precision":"year","title":"First tissue-agnostic approval","note":"Metastatic cancer (cancer that has spread). Pembrolizumab is approved for any solid tumour with mismatch-repair deficiency or microsatellite instability, the first cancer drug appr...","from":"metastatic-cancer","refs":["pembrolizumab"]},{"group":"history","date":"2017","precision":"year","title":"First trastuzumab biosimilar; neratinib; APHINITY","note":"HER2-positive breast cancer","from":"breast-her2-positive","refs":["trastuzumab-biosimilars","neratinib","aphinity"]},{"group":"history","date":"2017","precision":"year","title":"Four approvals in one year","note":"Acute myeloid leukaemia. Midostaurin (RATIFY), enasidenib, CPX-351, gemtuzumab re-approval; the first new AML drugs since 2000.","from":"aml","refs":["midostaurin","ratify","enasidenib","cpx-351"]},{"group":"history","date":"2017","precision":"year","title":"GATSBY: trastuzumab emtansine fails in the second line","note":"HER2-positive gastric cancer","from":"gastric-her2-positive","refs":[]},{"group":"history","date":"2017","precision":"year","title":"GeDDiS: gemcitabine-docetaxel not superior to doxorubicin","note":"Uterine sarcoma. Seddon and colleagues, Lancet Oncol; doxorubicin retained as first line.","from":"uterine-sarcoma","refs":["doxorubicin"]},{"group":"history","date":"2017","precision":"year","title":"Gemtuzumab ozogamicin returns to the market after withdrawal in 2010","note":"Acute myeloid leukaemia in children","from":"aml-paediatric","refs":["gemtuzumab-ozogamicin"]},{"group":"history","date":"2017","precision":"year","title":"HR-NBL1: busulfan-melphalan beats carboplatin-etoposide-melphalan","note":"High-risk neuroblastoma","from":"neuroblastoma-high-risk","refs":["hr-nbl1","busulfan","melphalan"]},{"group":"history","date":"2017","precision":"year","title":"HR-NBL1: busulfan-melphalan beats CEM; IL-2 adds no benefit (2018)","note":"Neuroblastoma (paediatric)","from":"neuroblastoma","refs":["hr-nbl1"]},{"group":"history","date":"2017","precision":"year","title":"Ibrutinib active in relapsed PCNSL","note":"Primary CNS lymphoma","from":"primary-cns-lymphoma","refs":["ibrutinib"]},{"group":"history","date":"2017","precision":"year","title":"IDH2 mutations define a SNUC subset","note":"Nasal cavity and paranasal sinus cancers (including esthesioneuroblastoma). Dogan and colleagues; Jo and colleagues.","from":"sinonasal","refs":[]},{"group":"history","date":"2017","precision":"year","title":"IDH2 R172 mutations found in most sinonasal undifferentiated carcinomas","note":"Sinonasal undifferentiated carcinoma (SNUC) and SWI/SNF-deficient sinonasal carcinoma","from":"sinonasal-undifferentiated-carcinoma","refs":["idh"]},{"group":"history","date":"2017","precision":"year","title":"IFM 2009: early transplant lengthens remission but not life after VRd","note":"Newly diagnosed multiple myeloma, transplant-eligible","from":"myeloma-transplant-eligible","refs":["vrd"]},{"group":"history","date":"2017","precision":"year","title":"InPACT opens","note":"Penile cancer. International phase 3 platform for node-positive penile cancer (NCT02305654).","from":"penile","refs":[]},{"group":"history","date":"2017","precision":"year","title":"InPACT opens in the United Kingdom, United States and Canada","note":"Node-positive and metastatic penile cancer","from":"node-positive-penile-cancer","refs":[]},{"group":"history","date":"2017","precision":"year","title":"ISG-STS 1001: neoadjuvant anthracycline-ifosfamide for high-risk STS","note":"Sarcomas (soft tissue, bone, GIST)","from":"sarcoma","refs":["isg-sts-1001"]},{"group":"history","date":"2017","precision":"year","title":"ISG-STS 1001: neoadjuvant epirubicin-ifosfamide improves survival in high-risk limb sarcoma","note":"Undifferentiated pleomorphic sarcoma (UPS)","from":"undifferentiated-pleomorphic-sarcoma","refs":["isg-sts-1001"]},{"group":"history","date":"2017","precision":"year","title":"ISG-STS 1001: neoadjuvant epirubicin-ifosfamide improves survival in high-risk limb sarcoma","note":"Soft tissue sarcoma of the extremity (localised and advanced)","from":"extremity-soft-tissue-sarcoma","refs":["isg-sts-1001"]},{"group":"history","date":"2017","precision":"year","title":"Japanese trial: PCI gives no survival benefit in extensive-stage disease with MRI surveillance","note":"Small-cell lung cancer","from":"sclc","refs":["prophylactic-cranial-irradiation"]},{"group":"history","date":"2017","precision":"year","title":"KEYNOTE-059 and ATTRACTION-2: PD-1 antibodies active in late-line gastric cancer","note":"PD-L1-high gastric cancer","from":"gastric-pdl1-high","refs":["pembrolizumab","nivolumab"]},{"group":"history","date":"2017","precision":"year","title":"KRAS and MAP2K1 mutations identified, establishing a neoplastic subset","note":"Rosai-Dorfman-Destombes disease","from":"rosai-dorfman-disease","refs":["ras-mapk"]},{"group":"history","date":"2017","precision":"year","title":"Kymriah: first CAR-T approved; TOWER confirms blinatumomab OS benefit","note":"Acute lymphoblastic leukaemia. ELIANA-based approval for ALL up to age 25; TOWER OS 7.7 vs 4.0 months.","from":"all-leukemia","refs":["tisagenlecleucel","eliana","tower"]},{"group":"history","date":"2017","precision":"year","title":"LATITUDE and STAMPEDE: abiraterone at first diagnosis","note":"Metastatic hormone-sensitive prostate cancer","from":"prostate-mhspc","refs":["latitude","stampede","abiraterone"]},{"group":"history","date":"2017","precision":"year","title":"LATITUDE and STAMPEDE: abiraterone in mHSPC","note":"Prostate cancer","from":"prostate","refs":["latitude","stampede"]},{"group":"history","date":"2017","precision":"year","title":"LUNA: pasireotide and everolimus active in lung and thymic tumours","note":"Lung neuroendocrine tumours (typical and atypical carcinoid)","from":"lung-net","refs":[]},{"group":"history","date":"2017","precision":"year","title":"MAJIC-ET: ruxolitinib not superior","note":"Essential thrombocythaemia (ET). Ruxolitinib matched but did not beat best available therapy after hydroxyurea failure, though it eased symptoms.","from":"essential-thrombocythaemia","refs":["majic-et","ruxolitinib"]},{"group":"history","date":"2017","precision":"year","title":"Midostaurin approved for advanced systemic mastocytosis","note":"Advanced systemic mastocytosis (aggressive SM, SM with an associated haematological neoplasm, mast cell leukaemia)","from":"advanced-systemic-mastocytosis","refs":["midostaurin"]},{"group":"history","date":"2017","precision":"year","title":"Midostaurin, enasidenib, gemtuzumab re-approval","note":"Acute myeloid leukaemia","from":"aml","refs":[]},{"group":"history","date":"2017","precision":"year","title":"MIKIE: intermittent vismodegib keeps efficacy with fewer side effects","note":"Locally advanced and metastatic basal cell carcinoma","from":"locally-advanced-bcc","refs":["vismodegib"]},{"group":"history","date":"2017","precision":"year","title":"MSLT-II: completion lymph node dissection abandoned; CheckMate 238 and COMBI-AD set adjuvant nivolumab and dabrafenib-trametinib","note":"Stage III melanoma (after surgery)","from":"stage-iii-melanoma","refs":["mslt-ii","checkmate-238","combi-ad"]},{"group":"history","date":"2017","precision":"year","title":"N107C: radiosurgery to the surgical cavity replaces post-operative whole-brain radiotherapy","note":"Brain metastases (secondary brain tumours)","from":"secondary-brain-tumours","refs":["radiosurgery-srs"]},{"group":"history","date":"2017","precision":"year","title":"NCI9673: nivolumab responses in refractory anal cancer","note":"Metastatic and recurrent anal squamous cell carcinoma","from":"metastatic-anal-cancer","refs":["nivolumab"]},{"group":"history","date":"2017","precision":"year","title":"Neoantigen quality in long-term survivors; the integrated TCGA portrait","note":"Pancreatic ductal adenocarcinoma. Survivors have both many high-quality neoantigens and abundant CD8 T cells, and lose those clones at metastasis; TCGA fixes the driver list and sh...","from":"pancreatic","refs":["paper-balachandran-neoantigen-quality-long-term-survivors-nature-2017","paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017","paper-connor-mutational-signatures-immune-pancreatic-jama-oncol-2017"]},{"group":"history","date":"2017","precision":"year","title":"NETTER-1 published; telotristat ethyl approved for carcinoid syndrome diarrhoea","note":"Small intestinal neuroendocrine tumours","from":"small-intestinal-net","refs":["netter-1","telotristat-ethyl"]},{"group":"history","date":"2017","precision":"year","title":"NICE refuses to fund vismodegib","note":"Basal cell carcinoma. TA489 recommendation 1.1 does not recommend vismodegib for metastatic or locally advanced basal cell carcinoma, on uncertain evidence and a cost per quality-a...","from":"basal-cell-carcinoma","refs":["vismodegib"]},{"group":"history","date":"2017","precision":"year","title":"Nivolumab active in refractory disease (NCI9673)","note":"Anal cancer (squamous cell carcinoma)","from":"anal","refs":["nivolumab"]},{"group":"history","date":"2017","precision":"year","title":"Nivolumab third line (ATTRACTION-2); pembrolizumab for MSI-high tumours","note":"Gastric & gastro-oesophageal junction cancer","from":"gastric","refs":["nivolumab","pembrolizumab","msi"]},{"group":"history","date":"2017","precision":"year","title":"Obinutuzumab first line (GALLIUM)","note":"Follicular lymphoma","from":"follicular-lymphoma","refs":["obinutuzumab"]},{"group":"history","date":"2017","precision":"year","title":"OlympiAD: olaparib beats chemotherapy in germline BRCA disease","note":"Metastatic triple-negative breast cancer","from":"tnbc-metastatic","refs":["olympiad","olaparib"]},{"group":"history","date":"2017","precision":"year","title":"One protein, five stains, and prospective sequencing measured against what patients receive","note":"Non-small-cell lung cancer. The Blueprint comparison shows three PD-L1 assays agree on tumour cells and SP142 does not.","from":"nsclc","refs":["paper-hirsch-j-thorac-oncol","paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017","paper-lee-clonal-history-small-cell-transformation-jco-2017","pdl1"]},{"group":"history","date":"2017","precision":"year","title":"PACIFIC: durvalumab after chemoradiation extends progression-free and overall survival","note":"Unresectable stage III non-small-cell lung cancer","from":"stage-iii-unresectable-nsclc","refs":["pacific","durvalumab","scott-antonia","paper-pacific-nejm-2017"]},{"group":"history","date":"2017","precision":"year","title":"PACIFIC: durvalumab consolidation in stage III","note":"Non-small-cell lung cancer","from":"nsclc","refs":["pacific","durvalumab"]},{"group":"history","date":"2017","precision":"year","title":"Pearlman: about one in six patients under 50 carries a germline predisposition variant","note":"Early-onset colorectal cancer (under 50)","from":"early-onset-colorectal","refs":["germline-testing","lynch-syndrome"]},{"group":"history","date":"2017","precision":"year","title":"Pediatric MATCH opens","note":"Rare cancers of childhood (NCI PDQ umbrella). Molecular assignment platform for any refractory childhood solid tumour.","from":"rare-childhood-cancers","refs":["pediatric-match"]},{"group":"history","date":"2017","precision":"year","title":"Pembrolizumab approved after KEYNOTE-087","note":"Relapsed and refractory classical Hodgkin lymphoma","from":"relapsed-refractory-hodgkin-lymphoma","refs":["pembrolizumab"]},{"group":"history","date":"2017","precision":"year","title":"Pembrolizumab approved for mismatch-repair-deficient solid tumours including small bowel adenocarcinoma","note":"Advanced and metastatic small bowel adenocarcinoma","from":"advanced-small-bowel-adenocarcinoma","refs":["pembrolizumab","msi"]},{"group":"history","date":"2017","precision":"year","title":"Pembrolizumab beats chemotherapy in second line (KEYNOTE-045)","note":"Bladder & urothelial cancer","from":"urothelial","refs":["pembrolizumab"]},{"group":"history","date":"2017","precision":"year","title":"Pembrolizumab cures chemoresistant GTN (Ghorani, Lancet)","note":"Gestational trophoblastic neoplasia","from":"gestational-trophoblastic","refs":["pembrolizumab"]},{"group":"history","date":"2017","precision":"year","title":"Pembrolizumab produces durable remissions in chemoresistant gestational trophoblastic neoplasia","note":"High-risk gestational trophoblastic neoplasia (FIGO score 7 or more, including ultra-high-risk)","from":"high-risk-gtn","refs":["pembrolizumab"]},{"group":"history","date":"2017","precision":"year","title":"Pembrolizumab receives the first tumour-agnostic approval, for mismatch repair deficient solid tumours","note":"Mismatch repair deficient (MSI-high) pancreatic ductal adenocarcinoma","from":"msi-high-pdac","refs":["pembrolizumab","merck"]},{"group":"history","date":"2017","precision":"year","title":"Pembrolizumab receives tumour-agnostic approval for mismatch repair-deficient cancers","note":"Microsatellite-unstable (MSI-high) gastric cancer","from":"gastric-msi-high","refs":["pembrolizumab","tumour-agnostic"]},{"group":"history","date":"2017","precision":"year","title":"Pembrolizumab responses reported in resistant trophoblastic tumours including intermediate types","note":"Placental-site trophoblastic tumour and epithelioid trophoblastic tumour","from":"placental-site-trophoblastic-tumour","refs":["pembrolizumab"]},{"group":"history","date":"2017","precision":"year","title":"Pembrolizumab tumour-agnostic approval for MSI-high cancers","note":"Small intestine cancer (small bowel adenocarcinoma). Small bowel adenocarcinoma is one of the eligible tumours.","from":"small-bowel","refs":["pembrolizumab"]},{"group":"history","date":"2017","precision":"year","title":"Pembrolizumab: first tumour-agnostic approval, dMMR","note":"Colorectal cancer. Based on KEYNOTE-016/164 and others; dMMR CRC becomes the model immunotherapy-responsive GI tumour.","from":"colorectal","refs":["pembrolizumab","msi","tumour-agnostic"]},{"group":"history","date":"2017","precision":"year","title":"Pembrolizumab: first tumour-agnostic approval, for mismatch-repair-deficient tumours","note":"Mismatch-repair-deficient endometrial cancer","from":"endometrial-mmr-deficient","refs":["pembrolizumab","msi"]},{"group":"history","date":"2017","precision":"year","title":"Plasma EBV DNA screening detects early nasopharyngeal carcinoma in Hong Kong","note":"Locoregionally advanced nasopharyngeal carcinoma (stage III to IVA)","from":"locoregionally-advanced-nasopharyngeal-carcinoma","refs":["plasma-ebv-dna"]},{"group":"history","date":"2017","precision":"year","title":"Plasma gets a threshold, and PARP resistance gets a mechanism","note":"Prostate cancer. Above a 2% tumour fraction, plasma reproduces every somatic mutation found in a matched metastatic biopsy, which is the number that makes a liquid biopsy reportabl...","from":"prostate","refs":["paper-wyatt-ctdna-tissue-concordance-mcrpc-jnci-2017","paper-quigley-brca2-reversion-cfdna-parp-resistance-cancer-discov-2017"]},{"group":"history","date":"2017","precision":"year","title":"Pooled nivolumab analysis: lower response rates in mucosal melanoma","note":"Mucosal melanoma","from":"mucosal-melanoma","refs":["nivolumab","ipilimumab"]},{"group":"history","date":"2017","precision":"year","title":"Proton CSI: equivalent control, fewer toxicities (Yock, Lancet Oncol)","note":"Medulloblastoma","from":"medulloblastoma","refs":["proton-therapy"]},{"group":"history","date":"2017","precision":"year","title":"RATIFY: midostaurin with 7+3 lengthens life; first targeted AML drug approved","note":"FLT3-mutated acute myeloid leukaemia","from":"aml-flt3","refs":["ratify","midostaurin"]},{"group":"history","date":"2017","precision":"year","title":"RB1 and TP53 loss drive lineage plasticity in models","note":"Neuroendocrine and small-cell prostate cancer","from":"prostate-nepc","refs":["tp53"]},{"group":"history","date":"2017","precision":"year","title":"Re-resection at four to eight weeks associated with longest survival","note":"Gallbladder cancer. Ethun and colleagues, ten US centres, 207 patients; a 2026 individual patient data meta-analysis found no difference by timing.","from":"gallbladder","refs":["paper-ethun-re-resection-timing-incidental-gallbladder-cancer-jama-surg-2017","paper-selvakumar-revision-surgery-timing-ipd-meta-analysis-hpb-2026"]},{"group":"history","date":"2017","precision":"year","title":"Resistance by changing cell type, and imaging moves in front of the biopsy","note":"Prostate cancer. Mu and Ku showed that losing TP53 and RB1 lets a prostate cancer cell switch on SOX2 and stop needing the androgen receptor, reversibly in the laboratory.","from":"prostate","refs":["paper-mu-sox2-lineage-plasticity-science-2017","paper-ahmed-promis-multiparametric-mri-lancet-2017","paper-ku-rb1-trp53-lineage-plasticity-science-2017"]},{"group":"history","date":"2017","precision":"year","title":"RESORCE: regorafenib works after sorafenib","note":"Advanced hepatocellular carcinoma (BCLC C)","from":"hcc-advanced","refs":["resorce","regorafenib"]},{"group":"history","date":"2017","precision":"year","title":"RESORCE: regorafenib, first second-line benefit; SARAH/SIRveNIB negative for Y-90 vs sorafenib","note":"Hepatocellular carcinoma","from":"hcc","refs":["resorce","sarah-sirvenib"]},{"group":"history","date":"2017","precision":"year","title":"Risk-stratified sequential treatment","note":"Post-transplant lymphoproliferative disorder (PTLD). Rituximab consolidation alone for complete responders (JCO 2017).","from":"post-transplant-lymphoproliferative-disorder","refs":["rituximab"]},{"group":"history","date":"2017","precision":"year","title":"RTOG 9601: bicalutamide with salvage radiotherapy improves survival","note":"Biochemical recurrence of prostate cancer","from":"prostate-bcr","refs":["bicalutamide"]},{"group":"history","date":"2017","precision":"year","title":"SARC006: neoadjuvant chemotherapy responses in a minority, fewer in NF1-associated tumours","note":"Malignant peripheral nerve sheath tumour (MPNST)","from":"malignant-peripheral-nerve-sheath-tumour","refs":["doxorubicin","ifosfamide"]},{"group":"history","date":"2017","precision":"year","title":"SARC028: pembrolizumab responses concentrated in UPS and dedifferentiated liposarcoma","note":"Undifferentiated pleomorphic sarcoma (UPS)","from":"undifferentiated-pleomorphic-sarcoma","refs":["pembrolizumab"]},{"group":"history","date":"2017","precision":"year","title":"Separate staging for HPV-positive disease (AJCC 8th edition)","note":"Oropharyngeal cancer (tonsil and base of tongue)","from":"oropharyngeal-cancer","refs":[]},{"group":"history","date":"2017","precision":"year","title":"Separate staging system for HPV-positive disease (AJCC 8th edition)","note":"HPV-positive oropharyngeal cancer","from":"hpv-positive-oropharyngeal-cancer","refs":[]},{"group":"history","date":"2017","precision":"year","title":"Short-course radiotherapy plus temozolomide extends survival from age 65 (CCTG CE.6)","note":"Glioma & glioblastoma","from":"glioblastoma","refs":["cctg-ce6"]},{"group":"history","date":"2017","precision":"year","title":"Side becomes a treatment decision, and non-V600 BRAF a separate disease","note":"Colorectal cancer. Across six randomised trials, EGFR antibodies helped left-sided RAS wild-type tumours (hazard ratio 0.75) and not right-sided ones (1.12); non-V600 BRAF mutation...","from":"colorectal","refs":["paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017","paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017","paper-jones-non-v600-braf-colorectal-jco-2017","paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017"]},{"group":"history","date":"2017","precision":"year","title":"Siegel and colleagues show a birth-cohort rise in colon and rectal cancer in young adults","note":"Early-onset colorectal cancer (under 50)","from":"early-onset-colorectal","refs":["colorectal-screening"]},{"group":"history","date":"2017","precision":"year","title":"Stage III moves, and so does the way tumours are read","note":"Lung cancer (all types). PACIFIC put durvalumab after chemoradiotherapy, reaching 42.9 percent five-year survival against 33.4; ALEX moved first-line ALK treatment to a brain-penet...","from":"lung-cancer","refs":["paper-spigel-pacific-five-year-survival-jco-2022","paper-peters-alex-alectinib-crizotinib-nejm-2017","paper-tracerx-100-nejm-2017","paper-abbosh-phylogenetic-ctdna-lung-cancer-nature-2017"]},{"group":"history","date":"2017","precision":"year","title":"STEVIE measures what the hedgehog pill is like to take","note":"Basal cell carcinoma. 1,215 patients in 36 countries: response 68.5 per cent in locally advanced disease, adverse events in 98 per cent and a median treatment duration of 8.6 month...","from":"basal-cell-carcinoma","refs":["stevie"]},{"group":"history","date":"2017","precision":"year","title":"SWOG S0777: bortezomib added to Rd lengthens life without transplant","note":"Newly diagnosed multiple myeloma, transplant-ineligible","from":"myeloma-transplant-ineligible","refs":["bortezomib","vrd"]},{"group":"history","date":"2017","precision":"year","title":"Takahashi: no survival benefit from prophylactic cranial irradiation with MRI surveillance","note":"Extensive-stage small-cell lung cancer","from":"extensive-stage-sclc","refs":["takahashi-pci","mri"]},{"group":"history","date":"2017","precision":"year","title":"TCGA analysis defines the pseudohypoxia and kinase clusters","note":"Hereditary pheochromocytoma and paraganglioma (SDHx, VHL, RET, NF1, MAX and TMEM127)","from":"hereditary-ppgl","refs":[]},{"group":"history","date":"2017","precision":"year","title":"TCGA sequencing confirms a shared clonal origin of both components with frequent TP53 mutation","note":"Uterine carcinosarcoma","from":"uterine-carcinosarcoma","refs":["tp53"]},{"group":"history","date":"2017","precision":"year","title":"Tisagenlecleucel approved: the first CAR T-cell therapy for any cancer, for children and young adults with relapsed B-ALL","note":"Relapsed and refractory acute lymphoblastic leukaemia in children","from":"all-paediatric-relapsed","refs":["tisagenlecleucel","eliana"]},{"group":"history","date":"2017","precision":"year","title":"Tisagenlecleucel: first CAR-T","note":"Acute lymphoblastic leukaemia","from":"all-leukemia","refs":[]},{"group":"history","date":"2017","precision":"year","title":"Tisagenlecleucel: the first CAR-T approval, for childhood ALL","note":"Leukaemia (all types)","from":"leukaemia","refs":["tisagenlecleucel"]},{"group":"history","date":"2017","precision":"year","title":"TNM 8th edition staging (IASLC/ITMIG)","note":"Thymoma and thymic carcinoma","from":"thymic-epithelial","refs":[]},{"group":"history","date":"2017","precision":"year","title":"TNM 8th edition: size-based T categories and node counts","note":"Pancreatic ductal adenocarcinoma. T1 to T3 by size (2 and 4 cm), N1 and N2 by one to three and four or more nodes; validated in 2,318 resections from three US centres and 8,960 SEE...","from":"pancreatic","refs":["tnm-staging"]},{"group":"history","date":"2017","precision":"year","title":"TNM staging for thymic tumours adopted in the eighth edition of the AJCC and UICC manuals","note":"Thymoma (WHO types A, AB, B1, B2 and B3)","from":"thymoma","refs":["staging-systems"]},{"group":"history","date":"2017","precision":"year","title":"Vemurafenib approved for BRAF V600E-mutant Erdheim-Chester disease (VE-BASKET)","note":"Erdheim-Chester disease","from":"erdheim-chester-disease","refs":["vemurafenib"]},{"group":"history","date":"2017","precision":"year","title":"Vemurafenib approved for ECD","note":"Erdheim-Chester disease, Rosai-Dorfman disease and other histiocytic neoplasms. First approval for any histiocytosis (VE-BASKET); November 2017.","from":"histiocytoses","refs":["vemurafenib"]},{"group":"history","date":"2017","precision":"year","title":"Vermilion lip cancer moves to the skin cancer staging chapter (AJCC 8th edition)","note":"Lip cancer","from":"lip-cancer","refs":[]},{"group":"history","date":"2017","precision":"year","title":"WHO classification confirms MAML2 fusion as diagnostic and prognostic","note":"Mucoepidermoid carcinoma","from":"mucoepidermoid-carcinoma","refs":[]},{"group":"history","date":"2017","precision":"year","title":"WHO classification of pancreatic tumours creates NET G3","note":"Grade 3 well-differentiated neuroendocrine tumour","from":"grade-3-net","refs":["net-grade-ki67"]},{"group":"history","date":"2017","precision":"year","title":"Z0011 at ten years: a positive sentinel node no longer means clearing the axilla","note":"Breast cancer (all types). Ten-year overall survival 86.3 percent without completion clearance against 83.6 percent with it.","from":"breast-cancer","refs":["acosog-z0011"]},{"group":"journal","date":"2017","precision":"year","title":"Biochimica et biophysica acta. Reviews on cancer founded","note":"Elsevier","from":"bba-reviews-on-cancer","refs":[]},{"group":"journal","date":"2017","precision":"year","title":"JCO clinical cancer informatics founded","note":"American Society of Clinical Oncology","from":"jco-clinical-cancer-informatics","refs":[]},{"group":"journal","date":"2017","precision":"year","title":"JCO Precision Oncology founded","note":"American Society of Clinical Oncology","from":"jco-precision-oncology","refs":[]},{"group":"journal","date":"2017","precision":"year","title":"JNCI cancer spectrum founded","note":"Oxford University Press","from":"jnci-cancer-spectrum","refs":[]},{"group":"law","date":"2017","precision":"year","title":"IVDR (EU In Vitro Diagnostic Regulation 2017/746)","note":"European Union, regulation.","from":"ivdr","refs":[]},{"group":"law","date":"2017","precision":"year","title":"Japan conditional early approval and time-limited approval","note":"Japan, statute.","from":"japan-conditional-early-approval","refs":[]},{"group":"law","date":"2017","precision":"year","title":"RACE for Children Act","note":"United States, statute.","from":"race-for-children-act","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"11 years' follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial","note":"Cameron D, Piccart-Gebhart MJ, Gelber RD, et al. The Lancet.","from":"paper-hera-b31-n9831-lancet-2017-update","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years","note":"Pan H, Gray R, Braybrooke J, et al. New England Journal of Medicine.","from":"paper-pan-n-engl-j-med","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"A European randomised controlled trial of the addition of etoposide to standard vincristine and carboplatin induction as part of an 18-month treatment programme...","note":"Gnekow AK, Walker DA, Kandels D, et al. European Journal of Cancer.","from":"paper-carboplatin-glioblastoma-eur-j-cancer-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"A prospective, multi-institutional, pathologist-based assessment of 4 immunohistochemistry assays for PD-L1 expression in non-small cell lung cancer","note":"Rimm DL, Han G, Taube JM, et al. JAMA Oncology.","from":"paper-rimm-pd-l1-assay-comparison-jama-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy","note":"Masuda N, Lee SJ, Ohtani S, et al. New England Journal of Medicine.","from":"paper-create-x-adjuvant-capecitabine-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Adrenergic nerves activate an angio-metabolic switch in prostate cancer","note":"Zahalka AH, Arnal-Estapé A, Maryanovich M, et al. Science.","from":"paper-zahalka-science","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"ALCANZA: brentuximab vedotin versus physician's choice in CD30-positive cutaneous T-cell lymphoma","note":"Prince HM, Kim YH, Horwitz SM, et al. The Lancet.","from":"paper-alcanza-brentuximab-vedotin-lancet-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer","note":"Peters S, Camidge DR, Shaw AT, et al. New England Journal of Medicine.","from":"paper-peters-alex-alectinib-crizotinib-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Altered interactions between unicellular and multicellular genes drive hallmarks of transformation in a diverse range of solid tumors","note":"Trigos AS, Pearson RB, Papenfuss AT, et al. Proceedings of the National Academy of Sciences.","from":"paper-trigos-proc-natl-acad-sci-u-s-a","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Analysis of circulating cell-free DNA identifies multiclonal heterogeneity of BRCA2 reversion mutations associated with resistance to PARP inhibitors","note":"Quigley D, Alumkal JJ, Wyatt AW, et al. Cancer Discovery.","from":"paper-quigley-brca2-reversion-cfdna-parp-resistance-cancer-discov-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Analysis of Plasma Epstein-Barr Virus DNA to Screen for Nasopharyngeal Cancer","note":"Chan KCA, Woo JKS, King A, et al. New England Journal of Medicine.","from":"paper-chan-n-engl-j-med","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"ANBL1221: irinotecan-temozolomide with temsirolimus or dinutuximab in relapsed or refractory neuroblastoma","note":"Mody R, Naranjo A, Van Ryn C, et al. The Lancet Oncology.","from":"paper-anbl1221-irinotecan-temozolomide-dinutuximab-mody-lancet-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Ancestral gene regulatory networks drive cancer","note":"Bussey KJ, Cisneros LH, Lineweaver CH, et al. Proceedings of the National Academy of Sciences.","from":"paper-bussey-proc-natl-acad-sci-u-s-a","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Androgen receptor pathway-independent prostate cancer is sustained through FGF signalling","note":"Bluemn EG, Coleman IM, Lucas JM, et al. Cancer Cell.","from":"paper-bluemn-double-negative-prostate-fgf-mapk-cancer-cell-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"APHINITY: adjuvant pertuzumab added to trastuzumab and chemotherapy in early HER2-positive breast cancer","note":"von Minckwitz G, Procter M, de Azambuja E, et al. New England Journal of Medicine.","from":"paper-aphinity-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Association of distinct mutational signatures with correlates of increased immune activity in pancreatic ductal adenocarcinoma","note":"Connor AA, Denroche RE, Jang GH, et al. JAMA Oncology.","from":"paper-connor-mutational-signatures-immune-pancreatic-jama-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Association of Optimal Time Interval to Re-resection for Incidental Gallbladder Cancer With Overall Survival: A Multi-Institution Analysis From the US Extrahepa...","note":"Ethun CG, Postlewait LM, Le N, et al. JAMA Surgery.","from":"paper-ethun-re-resection-timing-incidental-gallbladder-cancer-jama-surg-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled tri...","note":"Rittmeyer A, Barlesi F, Waterkamp D, et al. The Lancet.","from":"paper-keunchil-park-lancet-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study o...","note":"Davis C, Naci H, Gurpinar E, et al. BMJ.","from":"paper-davis-bmj","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Basch: asking patients to report symptoms online during chemotherapy improved survival","note":"Basch E, Deal AM, Dueck AC, et al. JAMA.","from":"paper-basch-epro-survival-jama-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Blinatumomab versus Chemotherapy for Advanced Acute Lymphoblastic Leukemia","note":"Kantarjian H, Stein A, Gökbuget N, et al. New England Journal of Medicine.","from":"paper-blinatumomab-all-leukemia-n-engl-j-med-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Brigatinib in patients with crizotinib-refractory ALK-positive non-small-cell lung cancer: a randomized, multicenter phase II trial (ALTA)","note":"Kim DW, Tiseo M, Ahn MJ, et al. Journal of Clinical Oncology.","from":"paper-alta-jco-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Broadening Eligibility Criteria to Make Clinical Trials More Representative: American Society of Clinical Oncology and Friends of Cancer Research Joint Research...","note":"Kim ES, Bruinooge SS, Roberts S, et al. Journal of Clinical Oncology.","from":"paper-kim-j-clin-oncol","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Cancer stem cells revisited","note":"Batlle E, Clevers H. Nature Medicine.","from":"paper-batlle-nat-med","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"CATNON: concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q codeletion","note":"van den Bent MJ, Baumert B, Erridge SC, et al. The Lancet.","from":"paper-catnon-lancet-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Cellular Senescence Promotes Adverse Effects of Chemotherapy and Cancer Relapse","note":"Demaria M, O'Leary MN, Chang J, et al. Cancer Discovery.","from":"paper-demaria-cancer-discov","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"CheckMate 026: first-line nivolumab in stage IV or recurrent non-small-cell lung cancer","note":"Carbone DP, Reck M, Paz-Ares L, et al. New England Journal of Medicine.","from":"paper-checkmate-026-first-line-nivolumab-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"CheckMate 238: adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma","note":"Weber J, Mandala M, Del Vecchio M, et al. New England Journal of Medicine.","from":"paper-checkmate-238-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"CIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancer","note":"Griffith M, Spies NC, Krysiak K, et al. Nature Genetics.","from":"paper-griffith-nat-genet","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Clinical practice guidelines on the evidence-based use of integrative therapies during and after breast cancer treatment","note":"Greenlee H, DuPont-Reyes MJ, Balneaves LG, et al. CA: A Cancer Journal for Clinicians.","from":"paper-greenlee-ca-cancer-j-clin","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Clonal Heterogeneity and Tumor Evolution: Past, Present, and the Future","note":"McGranahan N, Swanton C. Cell.","from":"paper-mcgranahan-cell","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Clonal history and genetic predictors of transformation into small-cell carcinomas from lung adenocarcinomas","note":"Lee JK, Lee J, Kim S, et al. Journal of Clinical Oncology.","from":"paper-lee-clonal-history-small-cell-transformation-jco-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Coffee consumption and health: umbrella review of meta-analyses of multiple health outcomes","note":"Poole R, Kennedy OJ, Roderick P, et al. BMJ.","from":"paper-poole-bmj","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Colorectal cancer incidence patterns in the United States, 1974-2013","note":"Siegel RL, Fedewa SA, Anderson WF, et al. JNCI: Journal of the National Cancer Institute.","from":"paper-siegel-colorectal-incidence-birth-cohort-jnci-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"COMBI-AD: adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma","note":"Long GV, Hauschild A, Santinami M, et al. New England Journal of Medicine.","from":"paper-combi-ad-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy","note":"Palmer AC, Sorger PK. Cell.","from":"paper-palmer-cell","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Combined circulating tumor DNA and protein biomarker-based liquid biopsy for the earlier detection of pancreatic cancers","note":"Cohen JD, Javed AA, Thoburn C, et al. PNAS.","from":"paper-cohen-ctdna-protein-liquid-biopsy-pancreatic-pnas-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Comparison of breast cancer molecular features and survival by African and European ancestry in The Cancer Genome Atlas","note":"Huo D, Hu H, Rhie SK, et al. JAMA Oncology.","from":"paper-huo-tcga-ancestry-breast-jama-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Concordance of circulating tumour DNA and matched metastatic tissue biopsy in prostate cancer","note":"Wyatt AW, Annala M, Aggarwal R, et al. Journal of the National Cancer Institute.","from":"paper-wyatt-ctdna-tissue-concordance-mcrpc-jnci-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT): an open-label, phase 3, randomised...","note":"Faivre-Finn C, Snee M, Ashcroft L, et al. The Lancet Oncology.","from":"paper-convert-lancet-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Confirmation of ProMisE: a genomics-based clinical classifier for endometrial cancer","note":"Talhouk A, McConechy MK, Leung S, et al. Cancer.","from":"paper-promise-talhouk-cancer-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Dabrafenib plus trametinib in previously untreated BRAF V600E-mutant metastatic non-small-cell lung cancer","note":"Planchard D, Smit EF, Groen HJM, et al. The Lancet Oncology.","from":"paper-planchard-dabrafenib-trametinib-first-line-lancet-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Dacomitinib versus gefitinib as first-line treatment for patients with EGFR-mutation-positive non-small-cell lung cancer (ARCHER 1050): a randomised, open-label...","note":"Wu YL, Cheng Y, Zhou X, et al. The Lancet Oncology.","from":"paper-archer-1050-lancet-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Defining a Cancer Dependency Map: which genes each cancer cell line cannot live without","note":"Tsherniak A, Vazquez F, Montgomery PG, et al. Cell.","from":"paper-depmap-tsherniak-cell-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Deleterious germline mutations in patients with apparently sporadic pancreatic adenocarcinoma","note":"Shindo K, Yu J, Suenaga M, et al. Journal of Clinical Oncology.","from":"paper-shindo-germline-sporadic-pancreatic-jco-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Dependency of a therapy-resistant state of cancer cells on a lipid peroxidase pathway","note":"Viswanathan VS, Ryan MJ, Dhruv HD, et al. Nature.","from":"paper-viswanathan-nature","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Distinct populations of inflammatory fibroblasts and myofibroblasts in pancreatic cancer","note":"Ohlund D, Handly-Santana A, Biffi G, et al. Journal of Experimental Medicine.","from":"paper-ohlund-caf-subtypes-mycaf-icaf-jem-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"DNA methylation-based classification and grading system for meningioma","note":"Sahm F, Schrimpf D, Stichel D, et al. The Lancet Oncology.","from":"paper-sahm-meningioma-methylation-lancet-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"DNA-encoded chemistry: enabling the deeper sampling of chemical space","note":"Goodnow RA, Dumelin CE, Keefe AD. Nature Reviews Drug Discovery.","from":"paper-goodnow-nat-rev-drug-discov","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Drug-tolerant persister cancer cells are vulnerable to GPX4 inhibition","note":"Hangauer MJ, Viswanathan VS, Ryan MJ, et al. Nature.","from":"paper-hangauer-nature","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Drugging the 'undruggable' cancer targets","note":"Dang CV, Reddy EP, Shokat KM, et al. Nature Reviews Cancer.","from":"paper-dang-nat-rev-cancer","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in KRAS wild-type advanced or metastatic colorectal cancer (CALGB/S...","note":"Venook AP, Niedzwiecki D, Lenz HJ, et al. JAMA.","from":"paper-venook-calgb-80405-cetuximab-vs-bevacizumab-jama-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Effect of interleukin-1β inhibition with canakinumab on incident lung cancer in patients with atherosclerosis: exploratory results from a randomised, double-bli...","note":"Ridker PM, MacFadyen JG, Thuren T, et al. The Lancet.","from":"paper-ridker-lancet","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical...","note":"Stupp R, Taillibert S, Kanner A, et al. JAMA.","from":"paper-stupp-jama","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Effectiveness of the Korean National Cancer Screening Program in Reducing Gastric Cancer Mortality","note":"Jun JK, Choi KS, Lee HY, et al. Gastroenterology.","from":"paper-jun-gastroenterology","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Efficacy and Safety of Anti-Trop-2 Antibody Drug Conjugate Sacituzumab Govitecan (IMMU-132) in Heavily Pretreated Patients With Metastatic Triple-Negative Breas...","note":"Bardia A, Mayer IA, Diamond JR, et al. Journal of Clinical Oncology.","from":"paper-sacituzumab-govitecan-tnbc-j-clin-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Elements of cancer immunity and the cancer-immune set point","note":"Chen DS, Mellman I. Nature.","from":"paper-chen-nature","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Emergency use of uridine triacetate for the prevention and treatment of life-threatening 5-fluorouracil and capecitabine toxicity","note":"Ma WW, Saif MW, El-Rayes BF, et al. Cancer.","from":"paper-vistogard-cancer-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukaemia","note":"Stein EM, DiNardo CD, Pollyea DA, et al. Blood.","from":"paper-enasidenib-idh2-stein-blood-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Epigenetic plasticity and the hallmarks of cancer","note":"Flavahan WA, Gaskell E, Bernstein BE. Science.","from":"paper-flavahan-science","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"ESPAC-4: adjuvant gemcitabine plus capecitabine versus gemcitabine alone after resection of pancreatic cancer","note":"Neoptolemos JP, Palmer DH, Ghaneh P, et al. The Lancet.","from":"paper-espac-4-gemcitabine-capecitabine-adjuvant-pancreatic-lancet-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"ESPEN guidelines on nutrition in cancer patients","note":"Arends J, Bachmann P, Baracos V, et al. Clinical nutrition (Edinburgh, Scotland).","from":"paper-arends-clin-nutr","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Esteva 2017: a deep neural network classifies skin cancer at dermatologist level","note":"Esteva A, Kuprel B, Novoa RA, et al. Nature.","from":"paper-esteva-skin-cancer-deep-learning-nature-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Extrachromosomal oncogene amplification drives tumour evolution and genetic heterogeneity","note":"Turner KM, Deshpande V, Beyter D, et al. Nature.","from":"paper-turner-nature","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"First-line ceritinib versus platinum-based chemotherapy in advanced ALK-rearranged non-small-cell lung cancer (ASCEND-4): a randomised, open-label, phase 3 stud...","note":"Soria JC, Tan DSW, Chiari R, et al. The Lancet.","from":"paper-ascend-4-lancet-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052): a multicentre, s...","note":"Balar AV, Castellano D, O'Donnell PH, et al. The Lancet Oncology.","from":"paper-pembrolizumab-urothelial-lancet-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Fitzmaurice 2017: the Global Burden of Disease estimate of cancer in 2015","note":"Global Burden of Disease Cancer Collaboration; Fitzmaurice C, Allen C, et al. JAMA Oncology.","from":"paper-fitzmaurice-gbd-cancer-2015-jamaoncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"From basic apoptosis discoveries to advanced selective BCL-2 family inhibitors","note":"Ashkenazi A, Fairbrother WJ, Leverson JD, et al. Nature Reviews Drug Discovery.","from":"paper-bcl-2-cll-nat-rev-drug-discov-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"GALLIUM: obinutuzumab for the first-line treatment of follicular lymphoma","note":"Marcus R, Davies A, Ando K, et al. New England Journal of Medicine.","from":"paper-gallium-obinutuzumab-first-line-follicular-lymphoma-marcus-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS)...","note":"Seddon B, Strauss SJ, Whelan J, et al. The Lancet Oncology.","from":"paper-seddon-lancet-oncol","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Germline BRCA2 mutations drive prostate cancers with distinct evolutionary trajectories","note":"Taylor RA, Fraser M, Livingstone J, et al. Nature Communications.","from":"paper-taylor-germline-brca2-evolutionary-trajectories-nat-commun-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Germline mutation status, pathological complete response, and disease-free survival in triple-negative breast cancer: secondary analysis of the GeparSixto rando...","note":"Hahnen E, Lederer B, Hauke J, et al. JAMA Oncology.","from":"paper-hahnen-geparsixto-germline-brca-jama-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"HER2/HER3 pathway in biliary tract malignancies; systematic review and meta-analysis: a potential therapeutic target?","note":"Galdy S, Lamarca A, McNamara MG, et al. Cancer Metastasis Reviews.","from":"paper-galdy-her2-biliary-tract-meta-analysis-cancer-metastasis-rev-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Hormonal maintenance therapy for women with low-grade serous cancer of the ovary or peritoneum","note":"Gershenson DM, Bodurka DC, Coleman RL, et al. Journal of Clinical Oncology.","from":"paper-gershenson-hormonal-maintenance-lgsoc-jco-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"HR-NBL1/SIOPEN: busulfan-melphalan versus carboplatin-etoposide-melphalan high-dose chemotherapy for high-risk neuroblastoma","note":"Ladenstein R, Pötschger U, Pearson ADJ, et al. The Lancet Oncology.","from":"paper-hr-nbl1-busulfan-melphalan-ladenstein-lancet-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures","note":"Davies H, Glodzik D, Morganella S, et al. Nature Medicine.","from":"paper-davies-nat-med","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Identification of targetable ALK rearrangements in pancreatic ductal adenocarcinoma","note":"Singhi AD, Ali SM, Lacy J, et al. Journal of the National Comprehensive Cancer Network.","from":"paper-singhi-alk-rearrangements-pancreatic-jnccn-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Identification of unique neoantigen qualities in long-term survivors of pancreatic cancer","note":"Balachandran VP, Luksza M, Zhao JN, et al. Nature.","from":"paper-balachandran-neoantigen-quality-long-term-survivors-nature-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"IELSG32 second randomisation: whole-brain radiotherapy or autologous stem cell transplant as consolidation in primary CNS lymphoma","note":"Ferreri AJM, Cwynarski K, Pulczynski E, et al. The Lancet Haematology.","from":"paper-ielsg32-wbrt-vs-asct-consolidation-ferreri-lancet-haematol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"IFM 2009: lenalidomide, bortezomib and dexamethasone with or without upfront transplantation for myeloma","note":"Attal M, Lauwers-Cances V, Hulin C, et al. New England Journal of Medicine.","from":"paper-ifm-2009-attal-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Impaired H3K36 methylation defines a subset of head and neck squamous cell carcinomas","note":"Papillon-Cavanagh S, Lu C, Gayden T, et al. Nature Genetics.","from":"paper-anthony-nichols-nat-genet-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Improved survival using specialized multidisciplinary board in sarcoma patients","note":"Blay JY, Soibinet P, Penel N, et al. Annals of Oncology.","from":"paper-florence-duffaud-ann-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Integrated genomic characterization of oesophageal carcinoma","note":"Cancer Genome Atlas Research Network, Analysis Working Group: Asan University, BC Cancer Agency, et al. Nature.","from":"paper-cancer-genome-atlas-research-nature","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Integrated genomic characterization of pancreatic ductal adenocarcinoma","note":"Cancer Genome Atlas Research Network (Raphael BJ, Hruban RH, Aguirre AJ, et al.). Cancer Cell.","from":"paper-tcga-pancreatic-integrated-characterisation-cancer-cell-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Integrated molecular meta-analysis of 1,000 paediatric high-grade and diffuse intrinsic pontine gliomas","note":"Mackay A, Burford A, Carvalho D, et al. Cancer Cell.","from":"paper-mackay-paediatric-hgg-cancer-cell-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Integrating evolutionary dynamics into treatment of metastatic castrate-resistant prostate cancer","note":"Zhang J, Cunningham JJ, Brown JS, et al. Nature Communications.","from":"paper-zhang-nat-commun","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Integration of Palliative Care Into Standard Oncology Care: American Society of Clinical Oncology Clinical Practice Guideline Update","note":"Ferrell BR, Temel JS, Temin S, et al. Journal of Clinical Oncology.","from":"paper-ferrell-j-clin-oncol","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Intertumoural heterogeneity within medulloblastoma subgroups","note":"Cavalli FMG, Remke M, Rampasek L, et al. Cancer Cell.","from":"paper-cavalli-medulloblastoma-subtypes-cancer-cell-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Ipatasertib plus paclitaxel versus placebo plus paclitaxel as first-line therapy for metastatic triple-negative breast cancer (LOTUS): a multicentre, randomised...","note":"Kim SB, Dent R, Im SA, et al. The Lancet Oncology.","from":"paper-kim-lotus-ipatasertib-tnbc-lancet-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"ISG-STS 1001: histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in high-risk soft tissue sarcoma","note":"Gronchi A, Ferrari S, Quagliuolo V, et al. The Lancet Oncology.","from":"paper-isg-sts-1001-gronchi-lancet-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Keap1 loss promotes Kras-driven lung cancer and results in dependence on glutaminolysis","note":"Romero R, Romero R, Sayin VI, et al. Nature Medicine.","from":"paper-romero-nat-med","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Lactate Metabolism in Human Lung Tumors","note":"Faubert B, Li KY, Cai L, et al. Cell.","from":"paper-faubert-cell","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"LATITUDE: abiraterone plus prednisone in newly diagnosed high-risk metastatic castration-sensitive prostate cancer","note":"Fizazi K, Tran N, Fein L, et al. New England Journal of Medicine.","from":"paper-latitude-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Le 2017: mismatch-repair deficiency predicts response to PD-1 blockade across twelve tumour types, leading to the first tissue-agnostic drug approval","note":"Le DT, Durham JN, Smith KN, et al. Science.","from":"paper-le-mmr-deficiency-science-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Li 2017: TIMER, a web server for estimating immune cells in tumour genomic data","note":"Li T, Fan J, Wang B, et al. Cancer Research.","from":"paper-li-timer-tumour-infiltrating-immune-cells-cancerres-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Limited heterogeneity of known driver gene mutations among the metastases of individual patients with pancreatic cancer","note":"Makohon-Moore AP, Zhang M, Reiter JG, et al. Nature Genetics.","from":"paper-makohon-moore-metastases-driver-homogeneity-nat-genet-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Long term effects of once-only flexible sigmoidoscopy screening after 17 years of follow-up","note":"Atkin W, Wooldrage K, Parkin DM, et al. The Lancet.","from":"paper-atkin-flexible-sigmoidoscopy-17-year-follow-up-lancet-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Long-Term Prognostic Risk After Neoadjuvant Chemotherapy Associated With Residual Cancer Burden and Breast Cancer Subtype","note":"Symmans WF, Wei C, Gould R, et al. Journal of Clinical Oncology.","from":"paper-symmans-rcb-long-term-prognosis-subtype-jco-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study","note":"Sekulic A, Migden MR, Basset-Seguin N, et al. BMC cancer.","from":"paper-erivance-bmc-cancer-2017-update","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Master Protocols to Study Multiple Therapies, Multiple Diseases, or Both","note":"Woodcock J, LaVange LM. New England Journal of Medicine.","from":"paper-woodcock-n-engl-j-med","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Melanoma staging: evidence-based changes in the AJCC eighth edition cancer staging manual","note":"Gershenwald JE, Scolyer RA, Hess KR, et al. CA: A Cancer Journal for Clinicians.","from":"paper-ajcc-8-melanoma-gershenwald-ca-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Molecular biomarkers for the evaluation of colorectal cancer: guideline from ASCP, CAP, AMP and ASCO","note":"Sepulveda AR, Hamilton SR, Allegra CJ, et al. Journal of Clinical Oncology.","from":"paper-sepulveda-molecular-biomarkers-colorectal-guideline-jco-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"MONARCH 2: Abemaciclib in Combination With Fulvestrant in Women With HR+/HER2- Advanced Breast Cancer Who Had Progressed While Receiving Endocrine Therapy","note":"Sledge GW, Toi M, Neven P, et al. Journal of Clinical Oncology.","from":"paper-nct02107703-j-clin-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"MSH2 loss in primary prostate cancer","note":"Guedes LB, Antonarakis ES, Schweizer MT, et al. Clinical Cancer Research.","from":"paper-guedes-msh2-loss-primary-prostate-ccr-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"MSLT-II: completion lymph node dissection or observation for sentinel-node metastasis in melanoma","note":"Faries MB, Thompson JF, Cochran AJ, et al. New England Journal of Medicine.","from":"paper-mslt-ii-faries-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"N107C/CEC.3: postoperative radiosurgery versus whole-brain radiotherapy after resection of a brain metastasis","note":"Brown PD, Ballman KV, Cerhan JH, et al. The Lancet Oncology.","from":"paper-n107c-brown-lancet-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"National Estimates of Genetic Testing in Women With a History of Breast or Ovarian Cancer","note":"Childers CP, Childers KK, Maggard-Gibbons M, et al. Journal of Clinical Oncology.","from":"paper-childers-j-clin-oncol","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"NCI9673: nivolumab for previously treated unresectable metastatic anal cancer","note":"Morris VK, Salem ME, Nimeiri H, et al. The Lancet Oncology.","from":"paper-nci9673-nivolumab-metastatic-anal-cancer-morris-lancet-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"NETTER-1: 177Lu-Dotatate for midgut neuroendocrine tumours progressing on octreotide","note":"Strosberg J, El-Haddad G, Wolin E, et al. New England Journal of Medicine.","from":"paper-netter-1-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Nivolumab alone or with ipilimumab in mucosal melanoma: pooled analysis","note":"D'Angelo SP, Larkin J, Sosman JA, et al. Journal of Clinical Oncology.","from":"paper-dangelo-mucosal-melanoma-pooled-jco-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142)","note":"Overman MJ, McDermott R, Leach JL, et al. Lancet Oncology.","from":"paper-overman-checkmate-142-nivolumab-dmmr-colorectal-lancet-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Non-homologous DNA end joining and alternative pathways to double-strand break repair","note":"Chang HHY, Pannunzio NR, Adachi N, et al. Nature reviews. Molecular cell biology.","from":"paper-chang-nat-rev-mol-cell-biol","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Non-V600 BRAF mutations define a clinically distinct molecular subtype of metastatic colorectal cancer","note":"Jones JC, Renfro LA, Al-Shamsi HO, et al. Journal of Clinical Oncology.","from":"paper-jones-non-v600-braf-colorectal-jco-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"OlympiAD: olaparib versus chemotherapy in metastatic breast cancer with a germline BRCA mutation","note":"Robson M, Im SA, Senkus E, et al. New England Journal of Medicine.","from":"paper-olympiad-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"OncoKB: A Precision Oncology Knowledge Base","note":"Chakravarty D, Gao J, Phillips SM, et al. JCO Precision Oncology.","from":"paper-chakravarty-jco-precis-oncol","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Osimertinib or Platinum-Pemetrexed in EGFR T790M-Positive Lung Cancer","note":"Mok TS, Wu Y-L, Ahn M-J, et al. New England Journal of Medicine.","from":"paper-osimertinib-nsclc-n-engl-j-med-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"PACIFIC: a year of durvalumab after chemoradiotherapy for stage III lung cancer","note":"Antonia SJ, Villegas A, Daniel D, et al. New England Journal of Medicine.","from":"paper-pacific-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Palliative radiation therapy for bone metastases: Update of an ASTRO Evidence-Based Guideline","note":"Lutz S, Balboni T, Jones J, et al. Practical radiation oncology.","from":"paper-lutz-pract-radiat-oncol","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"PARP inhibitors: Synthetic lethality in the clinic","note":"Lord CJ, Ashworth A. Science.","from":"paper-lord-science","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, ra...","note":"Coles CE, Griffin CL, Kirby AM, et al. The Lancet.","from":"paper-coles-lancet","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project","note":"Hirsch FR, McElhinny A, Stanforth D, et al. Journal of Thoracic Oncology.","from":"paper-hirsch-j-thorac-oncol","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma","note":"Bellmunt J, de Wit R, Vaughn DJ, et al. New England Journal of Medicine.","from":"paper-pembrolizumab-urothelial-n-engl-j-med-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study","note":"Bauml J, Seiwert TY, Pfister DG, et al. Journal of Clinical Oncology.","from":"paper-pembrolizumab-head-and-neck-j-clin-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Phylogenetic ctDNA analysis depicts early-stage lung cancer evolution","note":"Abbosh C, Birkbak NJ, Wilson GA, et al. Nature.","from":"paper-abbosh-phylogenetic-ctdna-lung-cancer-nature-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"PIVOT: follow-up of prostatectomy versus observation for early prostate cancer","note":"Wilt TJ, Jones KM, Barry MJ, et al. New England Journal of Medicine.","from":"paper-wilt-pivot-prostatectomy-observation-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Plasma circulating tumor DNA in pancreatic cancer patients is a prognostic marker","note":"Pietrasz D, Pecuchet N, Garlan F, et al. Clinical Cancer Research.","from":"paper-pietrasz-ctdna-prognostic-pancreatic-ccr-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Position paper: Rationale for the treatment of Wilms tumour in the UMBRELLA SIOP-RTSG 2016 protocol","note":"van den Heuvel-Eibrink MM, Hol JA, Pritchard-Jones K, et al. Nature reviews. Urology.","from":"paper-van-den-heuvel-eibrink-nat-rev-urol","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Pre-metastatic niches: organ-specific homes for metastases","note":"Peinado H, Zhang H, Matei IR, et al. Nature Reviews Cancer.","from":"paper-peinado-nat-rev-cancer","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Prevalence and Penetrance of Major Genes and Polygenes for Colorectal Cancer","note":"Win AK, Jenkins MA, Dowty JG, et al. Cancer Epidemiology, Biomarkers & Prevention.","from":"paper-win-cancer-epidemiol-biomarkers-prev","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer: retrospective analyses of the CRYSTAL...","note":"Tejpar S, Stintzing S, Ciardiello F, et al. JAMA Oncology.","from":"paper-tejpar-tumour-location-crystal-fire3-jama-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed a...","note":"Arnold D, Lueza B, Douillard JY, et al. Annals of Oncology.","from":"paper-arnold-primary-tumour-side-ras-wild-type-ann-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"PROMIS: diagnostic accuracy of multiparametric MRI and TRUS biopsy in prostate cancer","note":"Ahmed HU, El-Shater Bosaily A, Brown LC, et al. The Lancet.","from":"paper-ahmed-promis-multiparametric-mri-lancet-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 tr...","note":"Takahashi T, Yamanaka T, Seto T, et al. The Lancet Oncology.","from":"paper-takahashi-lancet-oncol","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Prospective comprehensive molecular characterization of lung adenocarcinomas for efficient patient matching to approved and emerging therapies","note":"Jordan EJ, Kim HR, Arcila ME, et al. Cancer Discovery.","from":"paper-jordan-prospective-lung-adenocarcinoma-msk-cancer-discov-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"PTLD-1: response to rituximab induction as a predictive marker allowing stratification into rituximab or R-CHOP consolidation in B-cell post-transplant lymphopr...","note":"Trappe RU, Dierickx D, Zimmermann H, et al. Journal of Clinical Oncology.","from":"paper-ptld-1-risk-stratified-sequential-treatment-trappe-jco-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Putting p53 in Context","note":"Kastenhuber ER, Lowe SW. Cell.","from":"paper-kastenhuber-cell","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer","note":"Shipley WU, Seiferheld W, Lukka HR, et al. New England Journal of Medicine.","from":"paper-rtog-9601-n-engl-j-med-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Randomized phase III trial evaluating the role of weight loss in adjuvant treatment of overweight and obese women with early breast cancer (Alliance A011401): s...","note":"Ligibel JA, Barry WT, Alfano C, et al. NPJ breast cancer.","from":"paper-ligibel-npj-breast-cancer","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"RATIFY: midostaurin added to chemotherapy for acute myeloid leukaemia with a FLT3 mutation","note":"Stone RM, Mandrekar SJ, Sanford BL, et al. New England Journal of Medicine.","from":"paper-ratify-midostaurin-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis and antiandrogen resistance","note":"Ku SY, Rosario S, Wang Y, et al. Science.","from":"paper-ku-rb1-trp53-lineage-plasticity-science-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","note":"Glynne-Jones R, Wyrwicz L, Tiret E, et al. Annals of Oncology.","from":"paper-esmo-rectal-cancer-guideline-ann-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Recurrent IDH2 R172X mutations in sinonasal undifferentiated carcinoma","note":"Jo VY, Chau NG, Hornick JL, Krane JF, Sholl LM. Modern Pathology.","from":"paper-jo-idh2-r172-mutations-snuc-mod-pathol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Renal cell carcinoma","note":"Hsieh JJ, Purdue MP, Signoretti S, et al. Nature reviews. Disease primers.","from":"paper-hsieh-nat-rev-dis-primers","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Repurposing metformin for the prevention of cancer and cancer recurrence","note":"Heckman-Stoddard BM, DeCensi A, Sahasrabuddhe VV, et al. Diabetologia.","from":"paper-andrea-decensi-diabetologia-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Revised international consensus Fukuoka guidelines for the management of IPMN of the pancreas (2017)","note":"Tanaka M, Fernández-Del Castillo C, Kamisawa T, et al. Pancreatology.","from":"paper-fukuoka-2017-consensus-guidelines-ipmn-pancreatology-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Role of Bone-Modifying Agents in Metastatic Breast Cancer: An American Society of Clinical Oncology-Cancer Care Ontario Focused Guideline Update","note":"Van Poznak C, Somerfield MR, Barlow WE, et al. Journal of Clinical Oncology.","from":"paper-van-poznak-j-clin-oncol","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"SARC028: pembrolizumab in advanced soft tissue and bone sarcoma","note":"Tawbi HA, Burgess M, Bolejack V, et al. The Lancet Oncology.","from":"paper-sarc028-pembrolizumab-sarcoma-tawbi-lancet-oncol-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"SCALP: scalp cooling to prevent hair loss during chemotherapy for early breast cancer","note":"Nangia J, Wang T, Osborne C, et al. JAMA.","from":"paper-scalp-trial-jama-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Selumetinib Plus Docetaxel Compared With Docetaxel Alone and Progression-Free Survival in Patients With KRAS-Mutant Advanced Non-Small Cell Lung Cancer: The SEL...","note":"Jänne PA, van den Heuvel MM, Barlesi F, et al. JAMA.","from":"paper-nct01933932-jama-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Short-Course Radiation plus Temozolomide in Elderly Patients with Glioblastoma","note":"Perry JR, Laperriere N, O'Callaghan CJ, et al. New England Journal of Medicine.","from":"paper-perry-n-engl-j-med","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Siegel 2017: Cancer statistics, 2017","note":"Siegel RL, Miller KD, Jemal A. CA: A Cancer Journal for Clinicians.","from":"paper-siegel-cancer-statistics-2017-cacancer-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer","note":"Mu P, Zhang Z, Benelli M, et al. Science.","from":"paper-mu-sox2-lineage-plasticity-science-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"STAMPEDE: adding abiraterone to hormone therapy at diagnosis of advanced prostate cancer","note":"James ND, de Bono JS, Spears MR, et al. New England Journal of Medicine.","from":"paper-stampede-abiraterone-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular...","note":"Li MM, Datto M, Duncavage EJ, et al. The Journal of molecular diagnostics.","from":"paper-li-j-mol-diagn","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Tai Chi Chih Compared With Cognitive Behavioral Therapy for the Treatment of Insomnia in Survivors of Breast Cancer: A Randomized, Partially Blinded, Noninferio...","note":"Irwin MR, Olmstead R, Carrillo C, et al. Journal of Clinical Oncology.","from":"paper-irwin-j-clin-oncol","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"The Essential Medicinal Chemistry of Curcumin","note":"Nelson KM, Dahlin JL, Bisson J, et al. Journal of medicinal chemistry.","from":"paper-nelson-j-med-chem","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"The high price of anticancer drugs: origins, implications, barriers, solutions","note":"Prasad V, De Jesús K, Mailankody S. Nature Reviews Clinical Oncology.","from":"paper-prasad-nat-rev-clin-oncol","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"The Varied Roles of Notch in Cancer","note":"Aster JC, Pear WS, Blacklow SC. Annual review of pathology.","from":"paper-aster-annu-rev-pathol","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"TRACERx first 100: tracking how lung cancers evolve, and how chromosomal chaos predicts relapse","note":"Jamal-Hanjani M, Wilson GA, McGranahan N, et al. (TRACERx Consortium). New England Journal of Medicine.","from":"paper-tracerx-100-nejm-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Transcriptional Addiction in Cancer","note":"Bradner JE, Hnisz D, Young RA. Cell.","from":"paper-bradner-cell","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Tumor and Microenvironment Evolution during Immunotherapy with Nivolumab","note":"Riaz N, Havel JJ, Makarov V, et al. Cell.","from":"paper-shailender-bhatia-cell-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Understanding CD30 biology and therapeutic targeting: a historical perspective providing insight into future directions","note":"van der Weyden CA, Pileri SA, Feldman AL, et al. Blood cancer journal.","from":"paper-cd30-hodgkin-lymphoma-blood-cancer-j-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Universal Patterns of Selection in Cancer and Somatic Tissues","note":"Martincorena I, Raine KM, Gerstung M, et al. Cell.","from":"paper-martincorena-cell","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Whole-genome landscapes of major melanoma subtypes","note":"Hayward NK, Wilmott JS, Waddell N, et al. Nature.","from":"paper-hayward-melanoma-whole-genome-nature-2017","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"Yoga for improving health-related quality of life, mental health and cancer-related symptoms in women diagnosed with breast cancer","note":"Cramer H, Lauche R, Klose P, et al. The Cochrane database of systematic reviews.","from":"paper-cramer-cochrane-database-syst-rev","refs":[]},{"group":"paper","date":"2017","precision":"year","title":"ZUMA-1: axicabtagene ciloleucel for refractory large B-cell lymphoma, the first CAR-T approved for lymphoma","note":"Neelapu SS, Locke FL, Bartlett NL, et al. New England Journal of Medicine.","from":"paper-zuma-1-axi-cel-nejm-2017","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"A phase I study of the SRC kinase inhibitor dasatinib with trastuzumab and paclitaxel as first line therapy for patients with HER2-overexpressing advanced breas...","note":"Oncotarget","from":"ander-urruticoechea","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"A Phase Ib Dose-Escalation Study of Encorafenib and Cetuximab with or without Alpelisib in Metastatic BRAF -Mutant Colorectal Cancer","note":"Cancer Discovery","from":"elena-elez","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"A preliminary report on the role of endoscopic endonasal nasopharyngectomy in recurrent rT3 and rT4 nasopharyngeal carcinoma","note":"Eur Arch Otorhinolaryngol","from":"mohd-zukiflee-abu-bakar","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"A Retrospective Analysis of Precision Medicine Outcomes in Patients With Advanced Cancer Reveals Improved Progression-Free Survival Without Increased Health Car...","note":"Journal of Oncology Practice","from":"derrick-haslem","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"A single dose of peripherally infused EGFRvIII-directed CAR T cells mediates antigen loss and induces adaptive resistance in patients with recurrent glioblastom...","note":"Science Translational Medicine","from":"marcela-maus","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Abiraterone for prostate cancer not previously treated with hormone therapy (STAMPEDE)","note":"NEJM","from":"nicholas-james","refs":["silke-gillessen"]},{"group":"person-paper","date":"2017","precision":"year","title":"Abiraterone plus Prednisone in Metastatic, Castration-Sensitive Prostate Cancer","note":"New England Journal of Medicine","from":"ye-dingwei","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Abiraterone plus prednisone in metastatic, castration-sensitive prostate cancer (LATITUDE)","note":"NEJM","from":"karim-fizazi","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Adjuvant dabrafenib plus trametinib in stage III BRAF-mutated melanoma (COMBI-AD)","note":"NEJM","from":"georgina-long","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Adjuvant nivolumab versus ipilimumab in resected stage III or IV melanoma (CheckMate 238)","note":"NEJM","from":"jeffrey-weber","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Adjuvant Pertuzumab and Trastuzumab in Early HER2-Positive Breast Cancer","note":"New England Journal of Medicine","from":"evandro-de-azambuja","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Adult desmoid tumors: biology, management and ongoing trials","note":"Current Opinion in Oncology","from":"nicolas-penel","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Alectinib versus crizotinib in untreated ALK-positive non-small-cell lung cancer (ALEX)","note":"NEJM","from":"ross-camidge","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"An immunogenic personal neoantigen vaccine for patients with melanoma","note":"Nature","from":"catherine-wu","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"An Open-Label, Randomized, Parallel, Phase III Trial Evaluating the Efficacy and Safety of Polymeric Micelle-Formulated Paclitaxel Compared to Conventional Crem...","note":"Cancer Research and Treatment","from":"sohn-joohyuk","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Aptasensor with Expanded Nucleotide Using DNA Nanotetrahedra for Electrochemical Detection of Cancerous Exosomes","note":"ACS Nano","from":"tan-weihong","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Association Between Use of a Scalp Cooling Device and Alopecia After Chemotherapy for Breast Cancer","note":"JAMA","from":"hope-rugo","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Association of minimal residual disease with superior survival outcomes in patients with multiple myeloma: a meta-analysis","note":"JAMA Oncology","from":"nikhil-munshi","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Axicabtagene ciloleucel CAR T-cell therapy in refractory large B-cell lymphoma (ZUMA-1)","note":"NEJM","from":"sattva-neelapu","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Bevacizumab and paclitaxel–carboplatin chemotherapy and secondary cytoreduction in recurrent, platinum-sensitive ovarian cancer (NRG Oncology/Gynecologic Oncolo...","note":"The Lancet Oncology","from":"robert-mannel","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"BRAF mutant colorectal cancer: prognosis, treatment, and new perspectives","note":"Annals of Oncology","from":"elena-elez","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Burden and centralised treatment in Europe of rare tumours: results of RARECAREnet-a population-based study","note":"Lancet Oncol","from":"ladislav-dusek","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Busulfan and melphalan versus carboplatin, etoposide, and melphalan as high-dose chemotherapy for high-risk neuroblastoma (HR-NBL1/SIOPEN)","note":"Lancet Oncology","from":"ruth-ladenstein","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"C/Can 2025: City Cancer Challenge, a new initiative to improve cancer care in cities","note":"The Lancet Oncology","from":"cary-adams","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"CEPI-a new global R&D organisation for epidemic preparedness and response","note":"Lancet","from":"trevor-mundel","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","note":"NEJM","from":"stephen-schuster","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Clinicoepidemiological profiles, clinical practices, and the impact of holistic care interventions on outcomes of pediatric hematolymphoid malignancies - A 7-ye...","note":"Indian Journal of Cancer","from":"narula-gaurav","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"CMTM6 maintains the expression of PD-L1 and regulates anti-tumour immunity","note":"Nature","from":"trapani-joseph","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4)","note":"Lancet","from":"paula-ghaneh","refs":["daniel-palmer"]},{"group":"person-paper","date":"2017","precision":"year","title":"Completion dissection or observation for sentinel-node metastasis in melanoma (MSLT-II)","note":"NEJM","from":"mark-faries","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Comprehensive molecular characterization of muscle-invasive bladder cancer","note":"Cell","from":"joaquim-bellmunt","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Computerized cytometry and wavelet analysis of follicular lesions for detecting malignancy: A pilot study in thyroid cytology","note":"Surgery","from":"michal-mekel","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Concurrent once-daily versus twice-daily chemoradiotherapy in patients with limited-stage small-cell lung cancer (CONVERT)","note":"Lancet Oncology","from":"corinne-faivre-finn","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"De-escalation strategies in HER2-positive early breast cancer (WSG-ADAPT HER2+/HR-)","note":"Annals of Oncology","from":"nadia-harbeck","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Deconstructing Niche Contributions to Bone Marrow Failure and Leukemogenesis in Shwachman-Diamond Syndrome","note":"Blood","from":"marc-raaijmakers","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Defective Cyclin B1 Induction in Trastuzumab-emtansine (T-DM1) Acquired Resistance in HER2-positive Breast Cancer","note":"Clinical Cancer Research","from":"joaquin-arribas","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Defining a cancer dependency map","note":"Cell","from":"francisca-vazquez","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Diagnostic accuracy of multi-parametric MRI and TRUS biopsy in prostate cancer (PROMIS)","note":"Lancet","from":"mark-emberton","refs":["hashim-ahmed"]},{"group":"person-paper","date":"2017","precision":"year","title":"Different manifestation of irradiation induced coronary artery disease detected with coronary computed tomography compared with matched non-irradiated controls","note":"Radiotherapy and Oncology","from":"martin-jan-schalij","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international...","note":"Lancet Oncology","from":"sant-chawla","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Dual-graft adult living donor liver transplantation: an innovative surgical procedure for live liver donor pool expansion","note":"Annals of Surgery","from":"lee-sung-gyu","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Duodenal Metastases From Renal Cell Carcinoma Presented With Melena: Review and Case Report","note":"Iranian Journal of Pathology","from":"seyed-rouhollah-miri","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Durvalumab after chemoradiotherapy in stage III non-small-cell lung cancer (PACIFIC)","note":"NEJM","from":"scott-antonia","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Early Detection of Molecular Residual Disease in Localized Lung Cancer by Circulating Tumor DNA Profiling","note":"Cancer Discovery","from":"maximilian-diehn","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016","note":"European Urology","from":"shahrokh-f-shariat","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"ECCO Essential Requirements for Quality Cancer Care: Colorectal Cancer. A critical review","note":"Critical Reviews in Oncology/Hematology","from":"geerard-beets","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Effect of axillary dissection vs no axillary dissection on 10-year overall survival among women with invasive breast cancer and sentinel node metastasis (ACOSOG...","note":"JAMA","from":"armando-giuliano","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal C...","note":"JAMA","from":"alan-venook","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Effect of tumor-treating fields plus maintenance temozolomide vs maintenance temozolomide alone on survival in patients with glioblastoma (EF-14)","note":"JAMA","from":"roger-stupp","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Effects of pioglitazone therapy on blood parameters, weight and BMI: a meta-analysis","note":"Diabetol Metab Syndr","from":"toni-vekov","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Efficacy and safety of bevacizumab-containing neoadjuvant therapy followed by interval debulking surgery in advanced ovarian cancer: Results from the ANTHALYA t...","note":"European Journal of Cancer","from":"roman-rouzier","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Efficacy of Neoadjuvant Carboplatin plus Docetaxel in Triple-Negative Breast Cancer: Combined Analysis of Two Cohorts","note":"Clinical Cancer Research","from":"priyanka-sharma","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Enasidenib in mutant IDH2 relapsed or refractory acute myeloid leukemia","note":"Blood","from":"eytan-stein","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm...","note":"Lancet Respiratory Medicine","from":"rolf-stahel","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"ESTRO ACROP consensus guideline on implementation and practice of stereotactic body radiotherapy for peripherally located early stage non-small cell lung cancer","note":"Radiother Oncol","from":"eric-felix-lartigau","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"European Association for Neuro-Oncology (EANO) guideline on the diagnosis and treatment of adult astrocytic and oligodendroglial gliomas","note":"The Lancet Oncology","from":"michael-weller","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Evaluation of Polygenic Risk Scores for Breast and Ovarian Cancer Risk Prediction in BRCA1 and BRCA2 Mutation Carriers","note":"JNCI: Journal of the National Cancer Institute","from":"rita-schmutzler","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"First patients treated with a 1.5 T MRI-Linac: clinical proof of concept of a high-precision, high-field MRI guided radiotherapy treatment","note":"Physics in Medicine and Biology","from":"bas-raaymakers","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"First-line pembrolizumab in cisplatin-ineligible patients with locally advanced and unresectable or metastatic urothelial cancer (KEYNOTE-052)","note":"Lancet Oncology","from":"arjun-balar","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Genotyping tumour DNA in cerebrospinal fluid and plasma of a HER2-positive breast cancer patient with brain metastases","note":"ESMO Open","from":"anna-sapino","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients","note":"Journal of Nuclear Medicine","from":"richard-baum","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Germline Mutation Status, Pathological Complete Response, and Disease-Free Survival in Triple-Negative Breast Cancer","note":"JAMA Oncology","from":"rita-schmutzler","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Global manufacturing of CAR T cell therapy","note":"Molecular Therapy Methods & Clinical Development","from":"bruce-levine","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in young children in 2015","note":"The Lancet","from":"shabir-madhi","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Gut microbiome influences efficacy of PD-1–based immunotherapy against epithelial tumors","note":"Science","from":"gerard-zalcman","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Histotype-tailored neoadjuvant chemotherapy versus standard chemotherapy in patients with high-risk soft-tissue sarcomas (ISG-STS 1001)","note":"Lancet Oncology","from":"alessandro-gronchi","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Inactivation of DNA repair triggers neoantigen generation and impairs tumour growth","note":"Nature","from":"alberto-bardelli","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Incidence and severity of self-reported chemotherapy side effects in routine care: A prospective cohort study","note":"PLOS ONE","from":"robyn-ward","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Individual patient-level meta-analysis of the performance of the Decipher genomic classifier in high-risk men after prostatectomy to predict development of meta...","note":"JCO","from":"daniel-spratt","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Inhibitory Effects of Dopamine Receptor D1 Agonist on Mammary Tumor and Bone Metastasis","note":"Scientific Reports","from":"nariaki-matsuura","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Innate immune landscape in early lung adenocarcinoma by paired single-cell analyses","note":"Cell","from":"miriam-merad","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Integrative Analysis Identifies Four Molecular and Clinical Subsets in Uveal Melanoma","note":"Cancer Cell","from":"sergio-roman-roman","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Interferon-γ derived from cytotoxic lymphocytes directly enhances their motility and cytotoxicity","note":"Cell Death & Disease","from":"ian-frazer","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glio...","note":"Lancet","from":"martin-van-den-bent","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Intertumoral heterogeneity within medulloblastoma subgroups","note":"Cancer Cell","from":"michael-taylor","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Interval Colorectal Cancer Incidence Among Subjects Undergoing Multiple Rounds of Fecal Immunochemical Testing","note":"Gastroenterology","from":"ernst-j-kuipers","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Ipilimumab Real-World Efficacy and Safety in Korean Melanoma Patients from the Korean Named-Patient Program Cohort","note":"Cancer Research and Treatment","from":"shin-sang-joon","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics","note":"The Lancet Oncology","from":"dancey-janet","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Lenalidomide maintenance compared with placebo in responding elderly patients with diffuse large B-cell lymphoma treated with first-line rituximab plus cyclopho...","note":"JCO","from":"catherine-thieblemont","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"LGL leukemia: from pathogenesis to treatment","note":"Blood","from":"thomas-loughran","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Liquid biopsies come of age: towards implementation of circulating tumour DNA","note":"Nature Reviews Cancer","from":"james-brenton","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia","note":"New England Journal of Medicine","from":"brian-druker","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Mechanisms of action and regulation of ATP-dependent chromatin-remodelling complexes","note":"Nature Reviews Molecular Cell Biology","from":"bradley-cairns","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with a FLT3 Mutation","note":"New England Journal of Medicine","from":"hubert-serve","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Midostaurin plus chemotherapy for acute myeloid leukemia with a FLT3 mutation (RATIFY)","note":"NEJM","from":"richard-stone","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"MiR-215-5p is a tumor suppressor in colorectal cancer targeting EGFR ligand epiregulin and its transcriptional inducer HOXB9","note":"Oncogenesis","from":"marek-svoboda","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade","note":"Science","from":"luis-diaz","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Mitochondrial activation chemicals synergize with surface receptor PD-1 blockade for T cell-dependent antitumor activity","note":"Proceedings of the National Academy of Sciences","from":"tasuku-honjo","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"MONARCH 3: Abemaciclib As Initial Therapy for Advanced Breast Cancer","note":"Journal of Clinical Oncology","from":"matthew-goetz","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Multidisciplinary management of head and neck cancer: First expert consensus using Delphi methodology from the Spanish Society for Head and Neck Cancer (part 1)","note":"Oral Oncology","from":"beatriz-castelo","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Mutational landscape of metastatic cancer revealed from prospective clinical sequencing of 10,000 patients","note":"Nature Medicine","from":"david-solit","refs":["michael-berger"]},{"group":"person-paper","date":"2017","precision":"year","title":"Neuroblastoma cells depend on HDAC11 for mitotic cell cycle progression and survival","note":"Cell Death & Disease","from":"angelika-eggert","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to two or more previous chemotherapy regimens (ATTRACTION-2)","note":"Lancet","from":"kang-yoon-koo","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Novel molecular subgroups for clinical classification and outcome prediction in childhood medulloblastoma: a cohort study","note":"Lancet Oncology","from":"steven-clifford","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Nuclear third nerve palsy as a presenting manifestation of breast carcinoma","note":"Neurology India","from":"vivek-lal","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation","note":"New England Journal of Medicine","from":"suzette-delaloge","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Overall survival results of a trial assessing patient-reported outcomes for symptom monitoring during routine cancer treatment","note":"JAMA","from":"ethan-basch","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Patients with metastatic melanoma treated with vemurafenib as monotherapy or in combination with cobimetinib.","note":"Journal of Clinical Oncology","from":"janja-ocvirk","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Patients' preference of trastuzumab administration (subcutaneous versus intravenous) in HER2-positive metastatic breast cancer: Results of the randomised Metasp...","note":"European Journal of Cancer","from":"joseph-gligorov","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Peering into the Deep: Characterizing the Internet Search Patterns of Patients with Gynecologic Cancers","note":"Journal of Cancer Education","from":"paris-ann-ingledew","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Pembrolizumab as second-line therapy for advanced urothelial carcinoma (KEYNOTE-045)","note":"NEJM","from":"joaquim-bellmunt","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results","note":"The Lancet","from":"jacob-schachter","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","note":"Nature","from":"ugur-sahin","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"PET-guided treatment in patients with advanced-stage Hodgkin's lymphoma (HD18): final results of an open-label, international, randomised phase 3 trial by the G...","note":"Lancet","from":"peter-borchmann","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors","note":"New England Journal of Medicine","from":"richard-baum","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Phase 3 trial of 177Lu-Dotatate for midgut neuroendocrine tumors (NETTER-1)","note":"NEJM","from":"jonathan-strosberg","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Phase I Study and Biomarker Analysis of Pyrotinib, a Novel Irreversible Pan-ErbB Receptor Tyrosine Kinase Inhibitor, in Patients With Human Epidermal Growth Fac...","note":"Journal of Clinical Oncology","from":"ma-fei","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Phylogenetic analysis of metastatic progression in breast cancer using somatic mutations and copy number aberrations","note":"Nature Communications","from":"magdolna-dank","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis","note":"Diabetes Ther","from":"toni-vekov","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Polyclonal secondary FGFR2 mutations drive acquired resistance to FGFR inhibition in patients with FGFR2 fusion-positive cholangiocarcinoma","note":"Cancer Discovery","from":"lipika-goyal","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Post prostatectomy outcomes of patients with high-risk prostate cancer treated with neoadjuvant androgen blockade","note":"Prostate Cancer and Prostatic Diseases","from":"rana-mckay","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Precisely Tracking Childhood Death","note":"Am J Trop Med Hyg","from":"trevor-mundel","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Prediction of overall survival for patients with metastatic castration-resistant prostate cancer: development of a prognostic model through a crowdsourced chall...","note":"Lancet Oncol","from":"sirkku-jyrkkio","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Predictive factors of response to immunotherapy—a review from the Spanish Melanoma Group (GEM)","note":"Annals of Translational Medicine","from":"enrique-espinosa","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Primary neuroendocrine breast carcinomas are associated with poor local control despite favourable biological profile: a retrospective clinical study","note":"BMC Cancer","from":"johanna-mattson","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy","note":"Cell","from":"padmanee-sharma","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non–Small-Cell Lung Cancer","note":"Journal of Clinical Oncology","from":"reinhard-buettner","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Radiotherapy and immunotherapy: a beneficial liaison?","note":"Nature Reviews Clinical Oncology","from":"ralph-weichselbaum","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Randomized Phase III Trial of Trastuzumab Plus Capecitabine With or Without Pertuzumab in Patients With Human Epidermal Growth Factor Receptor 2–Positive Metast...","note":"Journal of Clinical Oncology","from":"ander-urruticoechea","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Randomized Prospective Biomarker Trial of ERCC1 for Comparing Platinum and Nonplatinum Therapy in Advanced Non–Small-Cell Lung Cancer: ERCC1 Trial (ET)","note":"Journal of Clinical Oncology","from":"fiona-blackhall","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Retinal arterial blood flow and retinal changes in patients with sepsis: preliminary study using fluorescein angiography","note":"Critical Care","from":"kristo-erikson","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Review of Factors Related to the Thyroid Cancer Epidemic","note":"International Journal of Endocrinology","from":"xiao-haipeng","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Revisions to the International Neuroblastoma Response Criteria: A Consensus Statement From the National Cancer Institute Clinical Trials Planning Meeting","note":"Journal of Clinical Oncology","from":"julie-park","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Role of yoga in cancer patients: Expectations, benefits, and risks: A review","note":"Indian Journal of Palliative Care","from":"ajaikumar-b-s","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3)","note":"Lancet","from":"robert-coleman","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Ruxolitinib vs best available therapy for ET intolerant or resistant to hydroxycarbamide (MAJIC-ET)","note":"Blood","from":"claire-harrison","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Safety and activity of microRNA-loaded minicells in patients with recurrent malignant pleural mesothelioma: a first-in-man, phase 1, open-label, dose-escalation...","note":"The Lancet Oncology","from":"michael-boyer","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STAR...","note":"Cancer Discovery","from":"filippo-de-braud","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Safety, pharmacokinetics, and antitumour activity of trastuzumab deruxtecan (DS-8201), a HER2-targeting antibody–drug conjugate, in patients with advanced breas...","note":"The Lancet Oncology","from":"yonemori-kan","refs":["doi-toshihiko"]},{"group":"person-paper","date":"2017","precision":"year","title":"Scalable whole-exome sequencing of cell-free DNA reveals high concordance with metastatic tumors","note":"Nature Communications","from":"viktor-adalsteinsson","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Seizure and cognitive outcomes after resection of glioneuronal tumors in children","note":"Epilepsia","from":"sophia-varadkar","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Selective inhibition of FLT3 by gilteritinib in relapsed or refractory acute myeloid leukaemia: a multicentre, first-in-human, open-label, phase 1-2 study","note":"Lancet Oncology","from":"alexander-perl","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Serum Levels of MicroRNA miR-371a-3p: A Sensitive and Specific New Biomarker for Germ Cell Tumours","note":"European Urology","from":"carsten-bokemeyer","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Setting Quality Improvement Priorities for Women Receiving Systemic Therapy for Early-Stage Breast Cancer by Using Population-Level Administrative Data","note":"Journal of Clinical Oncology","from":"monika-krzyzanowska","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Simple Rules, Not So Simple: The Use of International Ovarian Tumor Analysis (IOTA) Terminology and Simple Rules in Inexperienced Hands in a Prospective Multice...","note":"Ultraschall in der Medizin - European Journal of Ultrasound","from":"helen-mertens","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Sunitinib: Ten Years of Successful Clinical Use and Study in Advanced Renal Cell Carcinoma","note":"The Oncologist","from":"robert-figlin","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Surgical versus non-surgical approach in primary desmoid-type fibromatosis patients: A nationwide prospective cohort from the French Sarcoma Group","note":"European Journal of Cancer","from":"nicolas-penel","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Targeted agents and immunotherapies: optimizing outcomes in melanoma","note":"Nature Reviews Clinical Oncology","from":"jason-luke","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Targeting a CAR to the TRAC locus with CRISPR/Cas9 enhances tumour rejection","note":"Nature","from":"michel-sadelain","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"The Microenvironmental Landscape of Brain Tumors","note":"Cancer Cell","from":"johanna-joyce","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"The natural history and patterns of metastases from mucosal melanoma: an analysis of 706 prospectively-followed patients","note":"Annals of Oncology","from":"guo-jun","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"The oncogenic role of circPVT1 in head and neck squamous cell carcinoma is mediated through the mutant p53/YAP/TEAD transcription-competent complex","note":"Genome Biology","from":"nikolaus-rajewsky","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Thirty-day mortality and five-year survival in thoracic surgery: “real-world” assessment of outcomes from a single-institution audit","note":"Tumori Journal","from":"gustavo-galmozzi","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Trastuzumab emtansine versus treatment of physician's choice in patients with previously treated HER2-positive metastatic breast cancer (TH3RESA)","note":"Lancet Oncology","from":"ian-krop","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Trends in Drug Utilization, Glycemic Control, and Rates of Severe Hypoglycemia, 2006-2013","note":"Diabetes Care","from":"joseph-ross","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Tumour-derived Interleukin 35 promotes pancreatic ductal adenocarcinoma cell extravasation and metastasis by inducing ICAM1 expression","note":"Nature Communications","from":"jihui-hao","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Two intermittent vismodegib dosing regimens in patients with multiple basal-cell carcinomas (MIKIE): a randomised, regimen-controlled, double-blind, phase 2 tri...","note":"The Lancet Oncology","from":"susana-puig","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Use of Prophylactic Mesh When Creating a Colostomy Does Not Prevent Parastomal Hernia","note":"Annals of Surgery","from":"pia-nasvall","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Validation of Contact-Free Sleep Monitoring Device with Comparison to Polysomnography","note":"J Clin Sleep Med","from":"shlomi-codish","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Vandetanib in patients with previously treated RET-rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial","note":"The Lancet Respiratory Medicine","from":"goto-koichi","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Vandetanib in pretreated patients with advanced non-small cell lung cancer-harboring RET rearrangement: a phase II clinical trial","note":"Annals of Oncology","from":"lee-se-hoon","refs":[]},{"group":"person-paper","date":"2017","precision":"year","title":"Venetoclax plus rituximab in relapsed or refractory chronic lymphocytic leukaemia: a phase 1b study","note":"Lancet Oncology","from":"john-seymour","refs":[]},{"group":"technology","date":"2017","precision":"year","title":"Autologous CAR-T manufacturing, batch by batch","note":"First use in humans or first approval, as the technology record states it.","from":"car-t-manufacturing-process","refs":[]},{"group":"technology","date":"2017","precision":"year","title":"CAR-T cell therapy","note":"First use in humans or first approval, as the technology record states it.","from":"car-t","refs":[]},{"group":"technology","date":"2017","precision":"year","title":"Personalised neoantigen (mRNA) vaccines","note":"First use in humans or first approval, as the technology record states it.","from":"neoantigen-mrna-vaccine","refs":[]},{"group":"technology","date":"2017","precision":"year","title":"Ring-gantry linacs (Halcyon, Ethos)","note":"First use in humans or first approval, as the technology record states it.","from":"ring-gantry-linac","refs":[]},{"group":"technology","date":"2017","precision":"year","title":"ZAP-X gyroscopic radiosurgery","note":"First use in humans or first approval, as the technology record states it.","from":"zap-x","refs":[]},{"group":"trial","date":"2017","precision":"year","title":"A Study of Aflibercept in Combination With FOLFIRI in Patients With Second-Line Metastatic Colorectal Cancer in Japan reported","from":"nct01882868","refs":["colorectal","ziv-aflibercept","irinotecan","fluorouracil"]},{"group":"trial","date":"2017","precision":"year","title":"ACOSOG Z0011 (Alliance) reported","note":"Ten-year overall survival 86.3 percent with sentinel node dissection alone against 83.6 percent with axillary clearance (hazard ratio 0.85, non-inferiority p=0.02).","from":"acosog-z0011","refs":["breast-cancer","breast-hr-positive","breast-her2-positive","tnbc"]},{"group":"trial","date":"2017","precision":"year","title":"AFFINITY reported","note":"Median overall survival 14.1 against 13.4 months (hazard ratio 0.95, 95 percent confidence interval 0.80 to 1.12) overall, and 11.0 against 10.9 months (0.97, 0.80 to 1.21) in the...","from":"affinity-custirsen","refs":["prostate","prostate-mcrpc","custirsen","cabazitaxel"]},{"group":"trial","date":"2017","precision":"year","title":"ALCANZA reported","note":"Brentuximab vedotin produced far more objective responses lasting at least four months than methotrexate or bexarotene; approved in November 2017.","from":"alcanza","refs":["cutaneous-t-cell-lymphoma","peripheral-t-cell-lymphoma","brentuximab-vedotin","methotrexate"]},{"group":"trial","date":"2017","precision":"year","title":"ALEX reported","note":"Median progression-free survival 34.8 vs 10.9 months (hazard ratio 0.43); 12-month brain progression 9.4% vs 41.4%; 5-year overall survival 62.5% vs 45.5%.","from":"alex","refs":["nsclc","alk-positive-nsclc","alectinib","crizotinib"]},{"group":"trial","date":"2017","precision":"year","title":"ALTA reported","note":"Confirmed objective response rate 45% (90 mg) and 54% (180 mg after a 7-day 90 mg lead-in); median progression-free survival 9.2 and 12.9 months (investigator-assessed, 8.0-month m...","from":"alta","refs":["nsclc","alk-positive-nsclc","brigatinib"]},{"group":"trial","date":"2017","precision":"year","title":"AMPLE reported","note":"Median total hospital days 10.0 against 12.0 (p=0.03, difference 2.92 days); breathlessness and quality of life equivalent.","from":"ample","refs":["nsclc","sclc","lung-cancer","pleural-mesothelioma"]},{"group":"trial","date":"2017","precision":"year","title":"ANBL1221 reported","note":"Objective response 52.9 percent with irinotecan, temozolomide and dinutuximab against 5.6 percent with temsirolimus in the randomised part; 41.5 percent across all 53 dinutuximab-t...","from":"anbl1221","refs":["neuroblastoma-high-risk","neuroblastoma","childhood-cancers","irinotecan"]},{"group":"trial","date":"2017","precision":"year","title":"APHINITY reported","note":"8-year iDFS HR 0.78; node-positive absolute +4.9%.","from":"aphinity","refs":["breast-her2-positive","her2-positive-early-breast-cancer","pertuzumab","trastuzumab"]},{"group":"trial","date":"2017","precision":"year","title":"ARCHER 1009: A Study Of Dacomitinib (PF-00299804) Vs. Erlotinib In The Treatment Of Advanced Non-Small Cell Lung Cancer reported","from":"nct01360554","refs":["nsclc","dacomitinib","erlotinib"]},{"group":"trial","date":"2017","precision":"year","title":"ARCHER 1050 reported","note":"Median progression-free survival 14.7 vs 9.2 months (hazard ratio 0.59, masked independent review); median overall survival 34.1 vs 26.8 months (hazard ratio 0.76) in a separate ma...","from":"nct01774721","refs":["nsclc","egfr-mutant-nsclc","dacomitinib","gefitinib"]},{"group":"trial","date":"2017","precision":"year","title":"ASCEND-4 reported","note":"Median progression-free survival 16.6 vs 8.1 months (hazard ratio 0.55, blinded independent review); response rate 72.5% vs 26.7%; overall survival not significantly different at t...","from":"nct01828099","refs":["nsclc","alk-positive-nsclc","ceritinib","pemetrexed"]},{"group":"trial","date":"2017","precision":"year","title":"ASCENDE-RT reported","note":"Nine-year biochemical progression-free survival 83 percent with a low-dose-rate brachytherapy boost against 62 percent with a dose-escalated external beam boost (multivariable haza...","from":"ascende-rt","refs":["prostate","prostate-intermediate-risk","prostate-high-risk"]},{"group":"trial","date":"2017","precision":"year","title":"Assess Efficacy & Safety of Selumetinib in Combination With Docetaxel in Patients Receiving 2nd Line Treatment for v-Ki-ras2 Kirsten Rat Sarcoma Viral reported","from":"nct01933932","refs":["nsclc","sclc","selumetinib","docetaxel"]},{"group":"trial","date":"2017","precision":"year","title":"ATTRACTION-2 reported","note":"Nivolumab improved overall survival over placebo in heavily pretreated advanced gastric cancer; approved in Japan in September 2017.","from":"attraction-2","refs":["gastric-pdl1-high","gastric","nivolumab"]},{"group":"trial","date":"2017","precision":"year","title":"AURA3 reported","note":"Median progression-free survival 10.1 against 4.4 months (hazard ratio 0.30, 95 percent confidence interval 0.23 to 0.41).","from":"aura3","refs":["egfr-mutant-nsclc","osimertinib","pemetrexed","carboplatin"]},{"group":"trial","date":"2017","precision":"year","title":"BILCAP reported","note":"OS 51.1 vs 36.4 months; ITT HR 0.81 (p=0.097), per-protocol HR 0.75.","from":"bilcap","refs":["cholangiocarcinoma","intrahepatic-cholangiocarcinoma","extrahepatic-cholangiocarcinoma","gallbladder"]},{"group":"trial","date":"2017","precision":"year","title":"BRF113928 cohort C (dabrafenib with trametinib, untreated BRAF V600E) reported","note":"Confirmed objective response 64 percent (23 of 36), with 6 percent complete responses; grade 3 or worse adverse events in 69 percent.","from":"brf113928","refs":["braf-v600e-nsclc","dabrafenib","trametinib","dabrafenib-trametinib"]},{"group":"trial","date":"2017","precision":"year","title":"CALGB/SWOG 80405 reported","note":"Median overall survival 30.0 with cetuximab against 29.0 months with bevacizumab: no significant difference.","from":"calgb-80405","refs":["colorectal","cetuximab","bevacizumab","folfox"]},{"group":"trial","date":"2017","precision":"year","title":"CATNON (EORTC 26053-22054) reported","note":"Adjuvant temozolomide: overall survival hazard ratio 0.65; 5-year survival 55.9% vs 44.1%. Concurrent temozolomide benefit confined to IDH-mutant tumours.","from":"catnon","refs":["glioblastoma","brain-tumours","idh-mutant-astrocytoma","temozolomide"]},{"group":"trial","date":"2017","precision":"year","title":"CCTG CE.6 / EORTC 26062-22061 (Perry trial) reported","note":"OS 9.3 vs 7.6 months, HR 0.67 (95% CI 0.56-0.80).","from":"cctg-ce6","refs":["glioblastoma","temozolomide"]},{"group":"trial","date":"2017","precision":"year","title":"CheckMate 026 reported","note":"Median progression-free survival 4.2 against 5.9 months (hazard ratio 1.15, p=0.25) and overall survival 14.4 against 13.2 months (hazard ratio 1.02): the primary endpoint was not...","from":"checkmate-026","refs":["nsclc","pdl1-high-nsclc","nivolumab","carboplatin"]},{"group":"trial","date":"2017","precision":"year","title":"CheckMate 238 reported","note":"12-month recurrence-free survival 70.5% vs 60.8% (HR 0.65); 4-year recurrence-free survival 51.7% vs 41.2%; no overall survival difference.","from":"checkmate-238","refs":["stage-iii-melanoma","melanoma","nivolumab","ipilimumab"]},{"group":"trial","date":"2017","precision":"year","title":"CLOCC reported","note":"Eight-year overall survival 35.9 against 8.9 percent with ablation added (hazard ratio 0.58).","from":"clocc","refs":["colorectal","folfox","bevacizumab","oxaliplatin"]},{"group":"trial","date":"2017","precision":"year","title":"COMBI-AD reported","note":"10-year RFS 48% vs 32%; DMFS 63% vs 48%.","from":"combi-ad","refs":["melanoma","braf-v600-melanoma","stage-iii-melanoma","dabrafenib-trametinib"]},{"group":"trial","date":"2017","precision":"year","title":"CONKO-005 reported","note":"Median disease-free survival 11.4 months with gemcitabine plus erlotinib and 11.4 months with gemcitabine; median overall survival 24.5 against 26.5 months.","from":"conko-005","refs":["pancreatic","resectable-pdac","erlotinib","gemcitabine"]},{"group":"trial","date":"2017","precision":"year","title":"CONVERT reported","note":"No significant difference; twice-daily 45 Gy remains standard.","from":"convert","refs":["sclc","limited-stage-sclc"]},{"group":"trial","date":"2017","precision":"year","title":"CREATE-X reported","note":"5-year DFS 74.1% vs 67.6% (HR 0.70); OS 89.2% vs 83.6% (HR 0.59). TNBC subgroup: DFS 69.8% vs 56.1% (HR 0.58), OS 78.8% vs 70.3% (HR 0.52).","from":"create-x","refs":["tnbc","tnbc-early","breast-hr-positive","capecitabine"]},{"group":"trial","date":"2017","precision":"year","title":"Depsipeptide (Romidepsin) in Treating Patients With Metastatic or Unresectable Soft Tissue Sarcoma reported","from":"nct00112463","refs":["alveolar-soft-part-sarcoma","angiosarcoma","epithelioid-sarcoma","chondrosarcoma"]},{"group":"trial","date":"2017","precision":"year","title":"ECHELON-1 reported","note":"6-year OS 93.9% vs 89.4%, HR 0.59.","from":"echelon-1","refs":["hodgkin-lymphoma","advanced-stage-classical-hodgkin-lymphoma","brentuximab-vedotin","doxorubicin"]},{"group":"trial","date":"2017","precision":"year","title":"Efficacy and Safety Study of TOOKAD® Soluble for Localised Prostate Cancer Compared to Active Surveillance reported","note":"Disease progression at 24 months in 28 percent after padeliporfin vascular-targeted photodynamic therapy against 58 percent under active surveillance (adjusted hazard ratio 0.34, 9...","from":"nct01310894","refs":["prostate","prostate-low-risk","padeliporfin"]},{"group":"trial","date":"2017","precision":"year","title":"ESPAC-4 reported","note":"Median overall survival 28.0 months with gemcitabine plus capecitabine against 25.5 months with gemcitabine alone (hazard ratio 0.82, p 0.032).","from":"espac-4","refs":["resectable-pdac","pancreatic","gemcitabine","capecitabine"]},{"group":"trial","date":"2017","precision":"year","title":"FIRES & SENTOR (sentinel node mapping) reported","note":"Sensitivity 97%, NPV 99.6% (FIRES).","from":"fires-sentor","refs":["endometrial"]},{"group":"trial","date":"2017","precision":"year","title":"FIRSTANA reported","note":"Median overall survival 24.5, 25.2 and 24.3 months for cabazitaxel 20 mg/m2, cabazitaxel 25 mg/m2 and docetaxel; neither cabazitaxel dose was superior.","from":"firstana","refs":["prostate","prostate-mcrpc","cabazitaxel","docetaxel"]},{"group":"trial","date":"2017","precision":"year","title":"GALLIUM reported","note":"Three-year progression-free survival 80.0 percent with obinutuzumab-chemotherapy against 73.3 percent with rituximab-chemotherapy (hazard ratio 0.66, p 0.001); more grade 3 to 5 ad...","from":"gallium","refs":["follicular-lymphoma","marginal-zone-lymphoma","non-hodgkin-lymphoma","obinutuzumab"]},{"group":"trial","date":"2017","precision":"year","title":"GATSBY reported","note":"Trastuzumab emtansine did not improve overall survival over taxane chemotherapy in previously treated HER2-positive gastric cancer.","from":"gatsby","refs":["gastric-her2-positive","gastric","trastuzumab-emtansine","docetaxel"]},{"group":"trial","date":"2017","precision":"year","title":"Glucarpidase Effect on Severe Delayed HDM-clearance in Children Treated With High-dose Mtx in ALL reported","from":"nct01305655","refs":["all-leukemia","glucarpidase"]},{"group":"trial","date":"2017","precision":"year","title":"IFM 2009 reported","note":"Early autologous transplant after RVD lengthened progression-free survival compared with RVD alone, with similar overall survival at first analysis.","from":"ifm-2009","refs":["myeloma-transplant-eligible","multiple-myeloma","lenalidomide","bortezomib"]},{"group":"trial","date":"2017","precision":"year","title":"IMPORT LOW reported","note":"5-year local relapse 0.5% (partial breast) vs 1.1% (whole breast), non-inferior; fewer breast changes.","from":"import-low","refs":["breast-hr-positive","breast-her2-positive","tnbc","breast-cancer"]},{"group":"trial","date":"2017","precision":"year","title":"ISG-STS 1001 reported","note":"Standard arm DFS HR ~0.45 vs tailored; OS 89% vs 64% at 46 months.","from":"isg-sts-1001","refs":["sarcoma","extremity-soft-tissue-sarcoma","undifferentiated-pleomorphic-sarcoma","ifosfamide"]},{"group":"trial","date":"2017","precision":"year","title":"J-ALEX reported","note":"Stopped at the second interim analysis for a large progression-free survival advantage of alectinib over crizotinib.","from":"j-alex","refs":["alk-positive-nsclc","alectinib","crizotinib"]},{"group":"trial","date":"2017","precision":"year","title":"LATITUDE reported","note":"OS HR 0.66.","from":"latitude","refs":["prostate","prostate-mhspc","abiraterone"]},{"group":"trial","date":"2017","precision":"year","title":"LDK378 Versus Chemotherapy in ALK Rearranged (ALK Positive) Patients Previously Treated With Chemotherapy (Platinum Doublet) and Crizotinib reported","from":"nct01828112","refs":["nsclc","ceritinib","pemetrexed","docetaxel"]},{"group":"trial","date":"2017","precision":"year","title":"LEGEND-2 reported","note":"ORR 88%, CR 68%, median PFS 15 months (Xi'an cohort, n = 57).","from":"legend-2","refs":["multiple-myeloma","ciltacabtagene-autoleucel"]},{"group":"trial","date":"2017","precision":"year","title":"LOTUS reported","note":"PFS 6.2 vs 4.9 months (HR 0.60, p 0.037); PTEN-low 6.2 vs 3.7 months (HR 0.59, p 0.18). Not confirmed by IPATunity130.","from":"lotus","refs":["tnbc","tnbc-metastatic","ipatasertib","paclitaxel"]},{"group":"trial","date":"2017","precision":"year","title":"MAJIC-ET reported","note":"Complete response within 1 year 46.6% (ruxolitinib) vs 44.2% (best available therapy), not significant; no difference in clots, bleeding or transformation at 2 years.","from":"majic-et","refs":["essential-thrombocythaemia","ruxolitinib","anagrelide"]},{"group":"trial","date":"2017","precision":"year","title":"MONARCH 3 reported","note":"PFS HR 0.54; OS 66.8 vs 53.7 months, HR 0.80 (NS).","from":"monarch-3","refs":["breast-hr-positive","abemaciclib"]},{"group":"trial","date":"2017","precision":"year","title":"MSLT-II reported","note":"No melanoma-specific survival benefit; lymphoedema 24% vs 6%.","from":"mslt-ii","refs":["melanoma","stage-iii-melanoma"]},{"group":"trial","date":"2017","precision":"year","title":"NCI9673 reported","note":"Nivolumab alone: objective response 24 percent in 37 previously treated patients. Nivolumab with ipilimumab did not improve progression-free survival (3.7 against 2.9 months, hazar...","from":"nci9673","refs":["metastatic-anal-cancer","anal","nivolumab","ipilimumab"]},{"group":"trial","date":"2017","precision":"year","title":"NETTER-1 reported","note":"PFS at 20 months 65.2% vs 10.8% (HR 0.21); ORR 18% vs 3%.","from":"netter-1","refs":["neuroendocrine","small-intestinal-net","lutathera","octreotide-lanreotide"]},{"group":"trial","date":"2017","precision":"year","title":"OlympiAD reported","note":"PFS 7.0 vs 4.2 months, HR 0.58; OS 19.3 vs 17.1 months, not significant.","from":"olympiad","refs":["tnbc","breast-hr-positive","tnbc-metastatic","hr-positive-metastatic-post-cdk46"]},{"group":"trial","date":"2017","precision":"year","title":"PACIFIC reported","note":"OS HR 0.68; 5-year OS 42.9% vs 33.4%.","from":"pacific","refs":["nsclc","stage-iii-unresectable-nsclc","durvalumab"]},{"group":"trial","date":"2017","precision":"year","title":"Phase 2 Trial of Prophylactic Rituximab Therapy for Prevention of CGVHD reported","from":"nct00186628","refs":["leukaemia","mantle-cell-lymphoma","rituximab","filgrastim"]},{"group":"trial","date":"2017","precision":"year","title":"PIVOT (Prostate Cancer Intervention Versus Observation Trial) reported","note":"All-cause mortality 61.3 against 66.8 percent (hazard ratio 0.84, 95 percent confidence interval 0.70 to 1.01, p=0.06) and prostate cancer mortality 7.4 against 11.4 percent (0.63...","from":"pivot","refs":["prostate","prostate-low-risk","prostate-intermediate-risk"]},{"group":"trial","date":"2017","precision":"year","title":"Pixantrone Dimaleate in Treating Patients With HER2-Negative Metastatic Breast Cancer reported","from":"nct01086605","refs":["breast-cancer","pixantrone"]},{"group":"trial","date":"2017","precision":"year","title":"PROFIT (Prostate Fractionated Irradiation Trial) reported","note":"Five-year biochemical and clinical failure-free survival 85 percent in both arms (hazard ratio 0.96, 90 percent confidence interval 0.77 to 1.2); no significant difference in grade...","from":"profit-trial","refs":["prostate","prostate-intermediate-risk"]},{"group":"trial","date":"2017","precision":"year","title":"PROMIS reported","note":"Multiparametric MRI sensitivity 93 percent against 48 percent for transrectal biopsy, at the cost of specificity (41 against 96 percent); as a triage test it would spare 27 percent...","from":"promis","refs":["prostate","prostate-low-risk","prostate-intermediate-risk"]},{"group":"trial","date":"2017","precision":"year","title":"PROSELICA reported","note":"Median overall survival 13.4 months at cabazitaxel 20 mg/m2 against 14.5 months at 25 mg/m2 (hazard ratio 1.024, upper bound 1.184, non-inferior); grade 3 or 4 adverse events 39.7...","from":"proselica","refs":["prostate","prostate-mcrpc","cabazitaxel","prednisone"]},{"group":"trial","date":"2017","precision":"year","title":"PTLD-1 reported","note":"Overall response 88 percent and complete remission 70 percent with risk-stratified sequential treatment; three-year response duration 82 percent; median overall survival 6.6 years...","from":"ptld-1","refs":["post-transplant-lymphoproliferative-disorder","non-hodgkin-lymphoma","rituximab","cyclophosphamide"]},{"group":"trial","date":"2017","precision":"year","title":"RATIFY (CALGB 10603) reported","note":"Median OS 74.7 vs 25.6 months; HR 0.78.","from":"ratify","refs":["aml","aml-flt3","midostaurin","cytarabine-7-3"]},{"group":"trial","date":"2017","precision":"year","title":"RESORCE reported","note":"OS 10.6 vs 7.8 months, HR 0.63.","from":"resorce","refs":["hcc","hcc-advanced","regorafenib"]},{"group":"trial","date":"2017","precision":"year","title":"RESPONSE-2 reported","note":"Haematocrit control at week 28: 62% vs 19%.","from":"response-2","refs":["polycythaemia-vera","ruxolitinib"]},{"group":"trial","date":"2017","precision":"year","title":"RTOG 9601 reported","note":"12-year overall survival 76.3% vs 71.3% (hazard ratio 0.77); benefit mainly with PSA above 0.7 ng/mL.","from":"rtog-9601","refs":["prostate","bicalutamide"]},{"group":"trial","date":"2017","precision":"year","title":"Samarium Sm 153 Lexidronam Pentasodium and 3-Dimensional Conformal Radiation Therapy or Intensity-Modulated Radiation Therapy in Treating Patients With Rising P...","from":"nct00551525","refs":["prostate","samarium-153-lexidronam"]},{"group":"trial","date":"2017","precision":"year","title":"SARAH and SIRveNIB reported","note":"OS not improved; fewer adverse events.","from":"sarah-sirvenib","refs":["hcc","sorafenib"]},{"group":"trial","date":"2017","precision":"year","title":"SARC028 reported","note":"Pembrolizumab produced objective responses mainly in undifferentiated pleomorphic sarcoma and dedifferentiated liposarcoma, with little activity in bone sarcomas.","from":"sarc028","refs":["undifferentiated-pleomorphic-sarcoma","liposarcoma","osteosarcoma","ewing-sarcoma"]},{"group":"trial","date":"2017","precision":"year","title":"SINS (surgical excision against imiquimod cream for basal cell carcinoma) reported","note":"Clinical success at three years 84 per cent with imiquimod against 98 per cent with surgery (relative risk 0.84, 98 per cent confidence interval 0.78 to 0.91, p<0.0001), and at fiv...","from":"sins-trial","refs":["basal-cell-carcinoma","skin-cancer","imiquimod"]},{"group":"trial","date":"2017","precision":"year","title":"SIOPEN HR-NBL1 reported","note":"BuMel > CEM (EFS 50% vs 38%); IL-2 adds no benefit to anti-GD2.","from":"hr-nbl1","refs":["neuroblastoma","neuroblastoma-high-risk","dinutuximab","busulfan"]},{"group":"trial","date":"2017","precision":"year","title":"STEVIE (vismodegib in ordinary practice) reported","note":"Investigator-assessed response 68.5 per cent in locally advanced and 36.9 per cent in metastatic basal cell carcinoma, with treatment-emergent adverse events in 98 per cent, seriou...","from":"stevie","refs":["basal-cell-carcinoma","locally-advanced-bcc","skin-cancer","vismodegib"]},{"group":"trial","date":"2017","precision":"year","title":"Stockholm III reported","note":"Delaying surgery after 5 x 5 Gy is non-inferior for local recurrence and has fewer postoperative complications.","from":"stockholm-iii","refs":["colorectal","rectal-cancer"]},{"group":"trial","date":"2017","precision":"year","title":"SYNERGY reported","note":"Median overall survival 23.4 against 22.0 months (hazard ratio 0.93, 95 percent confidence interval 0.79 to 1.10, p=0.415): no benefit.","from":"synergy-custirsen","refs":["prostate","prostate-mcrpc","custirsen","docetaxel"]},{"group":"trial","date":"2017","precision":"year","title":"Takahashi trial: prophylactic cranial irradiation with MRI surveillance in extensive-stage small-cell lung cancer reported","note":"Median overall survival 11.6 (PCI) vs 13.7 months (MRI surveillance), no benefit.","from":"takahashi-pci","refs":["sclc","extensive-stage-sclc"]},{"group":"trial","date":"2017","precision":"year","title":"TOWER reported","note":"OS 7.7 vs 4.0 months; HR 0.71.","from":"tower","refs":["all-leukemia","blinatumomab"]},{"group":"trial","date":"2017","precision":"year","title":"Vistogard Studies 1 and 2 reported","note":"Survival 96% (137 of 142) with uridine triacetate; historical supportive-care overdose cohort mortality 84% (21 of 25).","from":"vistogard-studies-1-2","refs":["uridine-triacetate"]},{"group":"trial","date":"2017","precision":"year","title":"ZUMA-1 reported","note":"High objective and complete response rates in refractory large B-cell lymphoma with durable remissions in a large minority; approved in October 2017.","from":"zuma-1","refs":["dlbcl","primary-mediastinal-b-cell-lymphoma","non-hodgkin-lymphoma","axicabtagene-ciloleucel"]},{"group":"regulatory","date":"2017-03-13","precision":"day","title":"Ribociclib: approval (US)","note":"With aromatase inhibitor, HR+/HER2- advanced breast cancer (MONALEESA-2)","from":"ribociclib","refs":[]},{"group":"regulatory","date":"2017-03-27","precision":"day","title":"Niraparib: approval (US)","note":"Maintenance in recurrent ovarian cancer regardless of BRCA (NOVA)","from":"niraparib","refs":[]},{"group":"regulatory","date":"2017-03-30","precision":"day","title":"Osimertinib: approval (US)","note":"Full approval (AURA3)","from":"osimertinib","refs":[]},{"group":"regulatory","date":"2017-03-31","precision":"day","title":"Palbociclib: approval (US)","note":"Full approval (PALOMA-2)","from":"palbociclib","refs":[]},{"group":"regulatory","date":"2017-04-28","precision":"day","title":"Midostaurin: approval (US)","note":"First FLT3 inhibitor approved","from":"midostaurin","refs":[]},{"group":"regulatory","date":"2017-05","precision":"month","title":"Dinutuximab (ch14.18) / dinutuximab beta: approval (EU)","note":"Dinutuximab beta (Qarziba)","from":"dinutuximab","refs":[]},{"group":"regulatory","date":"2017-05-01","precision":"day","title":"Durvalumab: approval (US)","note":"Urothelial carcinoma (accelerated; later withdrawn 2021)","from":"durvalumab","refs":[]},{"group":"regulatory","date":"2017-05-23","precision":"day","title":"Pembrolizumab: approval (US)","note":"MSI-H/dMMR solid tumours: first tumour-agnostic approval","from":"pembrolizumab","refs":[]},{"group":"regulatory","date":"2017-07-11","precision":"day","title":"Blinatumomab: approval (US)","note":"Full approval including Ph+ ALL","from":"blinatumomab","refs":[]},{"group":"regulatory","date":"2017-08","precision":"month","title":"Trastuzumab deruxtecan: designation (US)","note":"Breakthrough Therapy designation, HER2+ breast cancer","from":"trastuzumab-deruxtecan","refs":[]},{"group":"regulatory","date":"2017-08-01","precision":"day","title":"Enasidenib: approval (US)","note":"Single-arm AG221-C-001","from":"enasidenib","refs":[]},{"group":"regulatory","date":"2017-08-03","precision":"day","title":"CPX-351 (liposomal daunorubicin-cytarabine): approval (US)","note":"Adults","from":"cpx-351","refs":[]},{"group":"regulatory","date":"2017-08-17","precision":"day","title":"Inotuzumab ozogamicin: approval (US)","note":"INO-VATE","from":"inotuzumab-ozogamicin","refs":[]},{"group":"regulatory","date":"2017-08-17","precision":"day","title":"Olaparib: approval (US)","note":"Maintenance in platinum-sensitive recurrent ovarian cancer; tablet formulation","from":"olaparib","refs":[]},{"group":"regulatory","date":"2017-08-30","precision":"day","title":"Tisagenlecleucel: approval (US)","note":"First CAR-T approval in history","from":"tisagenlecleucel","refs":[]},{"group":"guideline","date":"2017-09","precision":"month","title":"NCCN 2017 updates for Acute myeloid leukaemia","note":"3 rows added. Anchored to FDA approvals of midostaurin (April 2017, RATIFY), CPX-351 (August 2017), enasidenib (August 2017) and the re-approval of gemtuzumab ozogamicin (September...","from":"aml","refs":["midostaurin","ratify","cpx-351","cpx-351-301"]},{"group":"guideline","date":"2017-09","precision":"month","title":"NCCN 2017 updates for HR-positive / HER2-negative breast cancer","note":"1 row added. Anchored to FDA approvals of ribociclib (March 2017) and abemaciclib (September 2017) after palbociclib (2015).","from":"breast-hr-positive","refs":["ribociclib","abemaciclib","palbociclib","monaleesa-2"]},{"group":"regulatory","date":"2017-09","precision":"month","title":"Bevacizumab: approval (US)","note":"First biosimilar (bevacizumab-awwb) approved","from":"bevacizumab","refs":[]},{"group":"regulatory","date":"2017-09-01","precision":"day","title":"Gemtuzumab ozogamicin: approval (US)","note":"Re-approval at lower fractionated dose for newly diagnosed and relapsed CD33+ AML (ALFA-0701)","from":"gemtuzumab-ozogamicin","refs":[]},{"group":"regulatory","date":"2017-09-26","precision":"day","title":"Lutetium-177 dotatate: approval (EU)","note":"EMA approval: first modern PRRT","from":"lutathera","refs":[]},{"group":"regulatory","date":"2017-09-28","precision":"day","title":"Abemaciclib: approval (US)","note":"With fulvestrant after endocrine therapy, and as monotherapy after chemotherapy (MONARCH 2/1)","from":"abemaciclib","refs":[]},{"group":"regulatory","date":"2017-10-18","precision":"day","title":"Axicabtagene ciloleucel: approval (US)","note":"Relapsed/refractory large B-cell lymphoma after ≥2 lines (ZUMA-1): second CAR-T ever approved","from":"axicabtagene-ciloleucel","refs":[]},{"group":"regulatory","date":"2017-11-30","precision":"day","title":"FoundationOne CDx / Liquid CDx: approval (US)","note":"FDA approval and parallel Medicare NCD: first FDA-approved broad CGP companion diagnostic","from":"foundationone-cdx","refs":[]},{"group":"regulatory","date":"2017-12-01","precision":"day","title":"Trastuzumab: approval (US)","note":"First trastuzumab biosimilar (Ogivri)","from":"trastuzumab","refs":[]},{"group":"regulatory","date":"2017-12-20","precision":"day","title":"Pertuzumab: approval (US)","note":"Adjuvant (APHINITY)","from":"pertuzumab","refs":[]}]},"route":"/years/2017/","neighbours":{"year":[{"id":"2016","kind":"year","name":"2016 in oncology","route":"/years/2016/"},{"id":"2018","kind":"year","name":"2018 in oncology","route":"/years/2018/"}]}}